

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
2 May 2002 (02.05.2002)

PCT

(10) International Publication Number  
WO 02/34913 A2

(51) International Patent Classification<sup>7</sup>: C12N 15/12,  
C07K 14/705, 16/28, A01K 67/027, G01N 33/53, C12Q  
1/68, G01N 33/68, 33/50, A61K 38/17

(21) International Application Number: PCT/US01/31454

(22) International Filing Date: 9 October 2001 (09.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/694,821 24 October 2000 (24.10.2000) US  
09/781,559 13 February 2001 (13.02.2001) US

(71) Applicant: PE CORPORATION (NY) [US/US]; 761  
Main Avenue, Norwalk, CT 06859 (US).

(72) Inventors: WEL, Ming-Hui; Celera Genomics Corpora-  
tion, 45 West Gude Drive C2-4#20, Rockville, MD 20850  
(US). YAN, Chunhua; Celera Genomics, 45 West Gude  
Drive, Rockville, MD 20850 (US). KETCHUM, Karen,  
A.; Celera Genomics, 45 West Gude Drive C2-4#20,  
Rockville, MD 20850 (US). CRAVCHIK, Anibal; Celera  
Genomics, 45 West Gude Drive, Rockville, MD 20850  
(US). DI FRANCESCO, Valentina; Celera Genomics, 45  
West Gude Drive, Rockville, MD 20850 (US). BEASLEY,  
Ellen, M.; Celera Genomics, 45 West Gude Drive,  
Rockville, MD 20850 (US).

(74) Agent: MILLMAN, Robert, A.; Celera Genomics, 45  
West Gude Drive C2-4#20, Rockville, MD 20850 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

[Continued on next page]

(54) Title: ISOLATED HUMAN G-PROTEIN COUPLED RECEPTORS, NUCLEIC ACID MOLECULES ENCODING HUMAN  
GPCR PROTEINS, AND USES THEREOF

```
1  TAATACACG  CTTAATGCG  CAGCAATTC  TCCTTCCTG  TGCGTGTCA
51  GCTGTGCTAC  GCGACATGTA  ATGGGTCTG  TGTGAATATC  CCGTCTCTCG
101  CCGGATCCCG  GGTGATTCG  TACATAGTG  TTGGCTTTGG  GGCTGTGCTG
151  GGTGTGTTTG  GAACCTCTG  GGTGATGAT  TCAATCTCTG  ATTTGACGCA
201  GGTGACCTCT  CCGACCAAT  TTCTGCTTC  CTCTCTGAGC  TGCGCTGATT
251  TCTTGTGTTG  TGTGACTGTG  ATGCTCTTCA  CATGCTGTCG  GACGCTGGAG
301  AGCTGCTGTG  ATTTGGGAG  GAGTTTGTG  ACTTCTCCCA  CTTCTGCGA
351  TGTGCAATTT  TGTATCTCT  CTCTCTTCCA  CTCTGCTCTC  ATCTGATGCG
401  ACAGGTACAT  TCGGTGACT  GACCCCTCG  TCTATGCTAC  CAGCTTCACG
451  CATCTCTGTG  CAGCAATTC  CATCAGCTG  TCTGCTGATC  TGCCCTCTAT
501  GTACAGCGGT  GCTGTGTTCT  ACACAGGTG  CTATGCGAT  GCGCTGCGAG
551  AATATCTGA  TGCCTTAAAC  TGTATAGGAG  GTTCTGACAC  CTTGTGAAT
601  CAAACTGCG  TGTGACAGA  TTTCTATCC  TTTCTTATAC  CTACCTTTAT
651  TATCATANT  CTGTATGTA  ACATATTCT  TGTGCTAGA  CGACGCGGA
701  AAAGATAGA  AATATCTGT  ACACAGACG  AATCATCTTC  AGAGATTAC
751  AAGCGCAGG  TGCGCAGGAG  AGAGAGAAA  CGAGCTAATA  CTTGTGGGT
801  CAGGTGTTA  GCAATTTAT  TTTGATGTT  ACCATATAC  CTTGATCTAT
851  TAATGATGC  CTTTATGGC  TTTATACCC  CTGCTCTAT  TTATGAGAT
901  TCTGTTGTT  GTGCTTATTA  TAATCAGCC  ATGATCTCT  TGATTATGC
951  TTTATTTAC  CCAATGTTTA  GAAAGCAAT  AAAGTTATT  GTAACGTCT
1001  AGGTTTAAA  GACATTTCA  GAAACATGA  ATTGTTTTC  TGAACATATA
1051  TAGGAGTTC  GATAGACAA  GTTCAGGAT  CT  (SEQ ID NO:1)
```

FEATURES:  
Start: 16  
Stop: 1051

HOMOLOGOUS PROTEIN:  
Top 10 BLAST Hits:

	Score	E
gi14565925 ref NP_003958.1  putative neurotransmitter receptor ...	293	2e-76
gi17657140 ref NP_055442.1  G protein-coupled receptor 57 >gi16...	252	5e-66
gi17657142 ref NP_055443.1  G protein-coupled receptor 58 >gi16...	246	2e-66
gi13941547 gb AAC82381.1  (AF069546) putative odorant receptor ...	215	6e-55
gi14028154 gb AAC9618.1  (AF083221) putative neurotransmitter ...	200	2e-50
gi14028153 gb AAC9617.1  (AF083221) putative neurotransmitter ...	197	1e-49
gi13646424 emb CA09599.1  (AJ011370) serotonin 4 receptor [Rat...	179	3e-46
gi13962388 emb CA06538.1  (AJ005433) dopamine D2/beta receptor...	176	3e-43
gi12661757 emb CAA73107.1  (Y12505) 5-HT4 receptor (Homo sapien...	176	4e-43
gi13326959 emb CAA73108.1  (Y12506) 5-HT4 receptor (Homo sapien...	176	4e-43

blast to cDST:

ESTs (from Genbank EST division)

	Score	E
gi17996957 gb AB062937.1 AB062937 HAZ-SM0005-110500-0C1-d09 SMO...	44	0.093

EXPRESSION INFORMATION FOR MODULATOR USE:  
Expression information from BLAST cDST hit:  
gi17996957|gb|AB062937.1 Human stomach

Expression information from PCR-based tissue screening panel:  
Human Placenta  
Human Kidney  
Human Skeletal muscle  
Human Liver  
Human Bone marrow  
Human Thymus

(57) Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the Human genome, the GPCR peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the GPCR peptides and methods of identifying modulators of the GPCR peptides.

WO 02/34913 A2



LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SL, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

**(84) Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## ISOLATED HUMAN G-PROTEIN COUPLED RECEPTORS, NUCLEIC ACID MOLECULES ENCODING HUMAN GPCR PROTEINS, AND USES THEREOF

### RELATED APPLICATIONS

5       The present application claims priority to U.S. Application No. 09.694.821, filed October 24, 2000 (CL000899) and U.S. Serial No. 09/781,559, filed February 13, 2001 (CL000899-CIP).

### FIELD OF THE INVENTION

10       The present invention is in the field of G-Protein coupled receptors (GPCRs) that are involved in cell signaling, particularly neurotransmitter signaling, recombinant DNA molecules, and protein production. The present invention specifically provides novel GPCR peptides and proteins and nucleic acid molecules encoding such peptide and protein molecules, all of which are useful in the development of human therapeutics and diagnostic compositions and methods.

### 15       BACKGROUND OF THE INVENTION

#### G-protein coupled receptors

20       G-protein coupled receptors (GPCRs) constitute a major class of proteins responsible for transducing a signal within a cell. GPCRs have three structural domains: an amino terminal extracellular domain, a transmembrane domain containing seven transmembrane segments, three extracellular loops, and three intracellular loops, and a carboxy terminal intracellular domain. Upon binding of a ligand to an extracellular portion of a GPCR, a signal is transduced within the cell that results in a change in a biological or physiological property of the cell. GPCRs, along with G-proteins and effectors (intracellular enzymes and channels modulated by G-proteins), are the components of a modular signaling system that connects the state of intracellular second  
25       messengers to extracellular inputs.

30       GPCR genes and gene-products are potential causative agents of disease (Spiegel *et al.*, *J. Clin. Invest.* 92:1119-1125 (1993); McKusick *et al.*, *J. Med. Genet.* 30:1-26 (1993)). Specific defects in the rhodopsin gene and the V2 vasopressin receptor gene have been shown to cause various forms of retinitis pigmentosum (Nathans *et al.*, *Annu. Rev. Genet.* 26:403-424(1992)), and nephrogenic diabetes insipidus (Holtzman *et al.*, *Hum. Mol. Genet.* 2:1201-1204 (1993)). These

receptors are of critical importance to both the central nervous system and peripheral physiological processes. Evolutionary analyses suggest that the ancestor of these proteins originally developed in concert with complex body plans and nervous systems.

The GPCR protein superfamily can be divided into five families: Family I, receptors typified by rhodopsin and the  $\beta$ 2-purinergeric receptor and currently represented by over 200 unique members (Dohlman *et al.*, *Annu. Rev. Biochem.* 60:653-688 (1991)); Family II, the parathyroid hormone/calcitonin/secretin receptor family (Juppner *et al.*, *Science* 254:1024-1026 (1991); Lin *et al.*, *Science* 254:1022-1024 (1991)); Family III, the metabotropic glutamate receptor family (Nakanishi, *Science* 258 597:603 (1992)); Family IV, the cAMP receptor family, important in the chemotaxis and development of *D. discoideum* (Klein *et al.*, *Science* 241:1467-1472 (1988)); and Family V, the fungal mating pheromone receptors such as STE2 (Kurjan, *Annu. Rev. Biochem.* 61:1097-1129 (1992)).

There are also a small number of other proteins that present seven putative hydrophobic segments and appear to be unrelated to GPCRs; they have not been shown to couple to G-proteins. *Drosophila* expresses a photoreceptor-specific protein, bride of sevenless (boss), a seven-transmembrane-segment protein that has been extensively studied and does not show evidence of being a GPCR (Hart *et al.*, *Proc. Natl. Acad. Sci. USA* 90:5047-5051 (1993)). The gene *frizzled* (*fz*) in *Drosophila* is also thought to be a protein with seven transmembrane segments. Like boss, *fz* has not been shown to couple to G-proteins (Vinson *et al.*, *Nature* 338:263-264 (1989)).

G proteins represent a family of heterotrimeric proteins composed of  $\alpha$ ,  $\beta$  and  $\gamma$  subunits, that bind guanine nucleotides. These proteins are usually linked to cell surface receptors, e.g., receptors containing seven transmembrane segments. Following ligand binding to the GPCR, a conformational change is transmitted to the G protein, which causes the  $\alpha$ -subunit to exchange a bound GDP molecule for a GTP molecule and to dissociate from the  $\beta\gamma$ -subunits. The GTP-bound form of the  $\alpha$ -subunit typically functions as an effector-modulating moiety, leading to the production of second messengers, such as cAMP (e.g., by activation of adenylyl cyclase), diacylglycerol or inositol phosphates. Greater than 20 different types of  $\alpha$ -subunits are known in humans. These subunits associate with a smaller pool of  $\beta$  and  $\gamma$  subunits. Examples of mammalian G proteins include Gi, Go, Gq, Gs and Gt. G proteins are described extensively in Lodish *et al.*, *Molecular Cell Biology*, (Scientific American Books Inc., New York, N.Y., 1995), the contents of which are incorporated herein by reference. GPCRs, G proteins and G protein-linked effector and second messenger systems have been reviewed in *The G-Protein Linked Receptor Fact Book*, Watson *et al.*, eds., Academic Press (1994).

### Aminergic GPCRs

One family of the GPCRS, Family II, contains receptors for acetylcholine, catecholamine, and indoleamine ligands (hereafter referred to as biogenic amines). The biogenic amine receptors (aminergic GPCRs) represent a large group of GPCRs that share a common evolutionary ancestor and which are present in both vertebrate (deuterostome), and invertebrate (protostome) lineages. This family of GPCRs includes, but is not limited to the 5-HT-like, the dopamine-like, the acetylcholine-like, the adrenaline-like and the melatonin-like GPCRs.

### Dopamine receptors

The understanding of the dopaminergic system relevance in brain function and disease developed several decades ago from three diverse observations following drug treatments. These were the observations that dopamine replacement therapy improved Parkinson's disease symptoms, depletion of dopamine and other catecholamines by reserpine caused depression and antipsychotic drugs blocked dopamine receptors. The finding that the dopamine receptor binding affinities of typical antipsychotic drugs correlate with their clinical potency led to the dopamine overactivity hypothesis of schizophrenia (Snyder, S.H., *Am J Psychiatry* 133, 197-202 (1976); Seeman, P. and Lee, T., *Science* 188, 1217-9 (1975)). Today, dopamine receptors are crucial targets in the pharmacological therapy of schizophrenia, Parkinson's disease, Tourette's syndrome, tardive dyskinesia and Huntington's disease. The dopaminergic system includes the nigrostriatal, mesocorticolimbic and tuberoinfundibular pathways. The nigrostriatal pathway is part of the striatal motor system and its degeneration leads to Parkinson's disease; the mesocorticolimbic pathway plays a key role in reinforcement and in emotional expression and is the desired site of action of antipsychotic drugs; the tuberoinfundibular pathways regulates prolactin secretion from the pituitary.

Dopamine receptors are members of the G protein coupled receptor superfamily, a large group proteins that share a seven helical membrane-spanning structure and transduce signals through coupling to heterotrimeric guanine nucleotide-binding regulatory proteins (G proteins). Dopamine receptors are classified into subfamilies: D1-like (D1 and D5) and D2-like (D2, D3 and D4) based on their different ligand binding profiles, signal transduction properties, sequence homologies and genomic organizations (Civelli, O., Bunzow, J.R. and Grandy, D.K., *Annu Rev Pharmacol Toxicol* 33, 281-307 (1993)). The D1-like receptors, D1 and D5, stimulate cAMP synthesis through coupling with Gs-like proteins and their genes do not contain introns within their protein coding regions. On the other hand, the D2-like receptors, D2, D3 and D4, inhibit cAMP

synthesis through their interaction with Gi-like proteins and share a similar genomic organization which includes introns within their protein coding regions.

### Serotonin receptors

Serotonin (5-Hydroxytryptamine; 5-HT) was first isolated from blood serum, where it was shown to promote vasoconstriction (Rapport, M.M., Green, A.A. and Page, I.H., *J Biol Chem* 176, 1243-1251 (1948). Interest on a possible relationship between 5-HT and psychiatric disease was spurred by the observations that hallucinogens such as LSD and psilocybin inhibit the actions of 5-HT on smooth muscle preparations (Gaddum, J.H. and Hameed, K.A., *Br J Pharmacol* 9, 240-248 (1954)). This observation lead to the hypothesis that brain 5-HT activity might be altered in psychiatric disorders (Wooley, D.W. and Shaw, E., *Proc Natl Acad Sci U S A* 40, 228-231 (1954); Gaddum, J.H. and Picarelli, Z.P., *Br J Pharmacol* 12, 323-328 (1957)). This hypothesis was strengthened by the introduction of tricyclic antidepressants and monoamine oxidase inhibitors for the treatment of major depression and the observation that those drugs affected noradrenaline and 5-HT metabolism. Today, drugs acting on the serotonergic system have been proved to be effective in the pharmacotherapy of psychiatric diseases such as depression, schizophrenia, obsessive-compulsive disorder, panic disorder, generalized anxiety disorder and social phobia as well as migraine, vomiting induced by cancer chemotherapy and gastric motility disorders.

Serotonin receptors represent a very large and diverse family of neurotransmitter receptors. To date thirteen 5-HT receptor proteins coupled to G proteins plus one ligand-gated ion channel receptor (5-HT3) have been described in mammals. This receptor diversity is thought to reflect serotonin's ancient origin as a neurotransmitter and a hormone as well as the many different roles of 5-HT in mammals. The 5-HT receptors have been classified into seven subfamilies or groups according to their different ligand-binding affinity profiles, molecular structure and intracellular transduction mechanisms (Hoyer, D. et al., *Pharmacol. Rev.* 46, 157-203 (1994)).

### Adrenergic GPCRs

The adrenergic receptors comprise one of the largest and most extensively characterized families within the G-protein coupled receptor "superfamily". This superfamily includes not only adrenergic receptors, but also muscarinic, cholinergic, dopaminergic, serotonergic, and histaminergic receptors. Numerous peptide receptors include glucagon, somatostatin, and vasopressin receptors, as well as sensory receptors for vision (rhodopsin), taste, and olfaction, also belong to this growing family. Despite the diversity of signalling molecules, G-protein coupled receptors all possess a similar overall primary structure, characterized by 7 putative

membrane-spanning .alpha. helices (Probst et al., 1992). In the most basic sense, the adrenergic receptors are the physiological sites of action of the catecholamines, epinephrine and norepinephrine. Adrenergic receptors were initially classified as either .alpha. or .beta. by Ahlquist, who demonstrated that the order of potency for a series of agonists to evoke a physiological response was distinctly different at the 2 receptor subtypes (Ahlquist, 1948). Functionally, .alpha. adrenergic receptors were shown to control vasoconstriction, pupil dilation and uterine inhibition, while .beta. adrenergic receptors were implicated in vasorelaxation, myocardial stimulation and bronchodilation (Regan et al., 1990). Eventually, pharmacologists realized that these responses resulted from activation of several distinct adrenergic receptor subtypes. .beta. adrenergic receptors in the heart were defined as .beta..sub.1, while those in the lung and vasculature were termed .beta..sub.2 (Lands et al., 1967).

.alpha. Adrenergic receptors, meanwhile, were first classified based on their anatomical location, as either pre or post-synaptic (.alpha..sub.2 and .alpha..sub.1, respectively) (Langer et al., 1974). This classification scheme was confounded, however, by the presence of .alpha..sub.2 receptors in distinctly non-synaptic locations, such as platelets (Berthelsen and Pettinger, 1977). With the development of radioligand binding techniques, .alpha. adrenergic receptors could be distinguished pharmacologically based on their affinities for the antagonists prazosin or yohimbine (Stark, 1981). Definitive evidence for adrenergic receptor subtypes, however, awaited purification and molecular cloning of adrenergic receptor subtypes. In 1986, the genes for the hamster .beta..sub.2 (Dickson et al., 1986) and turkey .beta..sub.1 adrenergic receptors (Yarden et al., 1986) were cloned and sequenced. Hydropathy analysis revealed that these proteins contain 7 hydrophobic domains similar to rhodopsin, the receptor for light. Since that time the adrenergic receptor family has expanded to include 3 subtypes of .beta. receptors (Emorine et al., 1989), 3 subtypes of .alpha..sub.1 receptors (Schwinn et al., 1990), and 3 distinct types of .beta..sub.2 receptors (Lomasney et al., 1990).

The cloning, sequencing and expression of alpha receptor subtypes from animal tissues has led to the subclassification of the alpha 1 receptors into alpha 1d (formerly known as alpha 1a or 1a/1d), alpha 1b and alpha 1a (formerly known as alpha 1c) subtypes. Each alpha 1 receptor subtype exhibits its own pharmacologic and tissue specificities. The designation "alpha 1a" is the appellation recently approved by the IUPHAR Nomenclature Committee for the previously designated "alpha 1c" cloned subtype as outlined in the 1995 Receptor and Ion Channel Nomenclature Supplement (Watson and Girdlestone, 1995). The designation alpha 1a is used throughout this application to refer to this subtype. At the same time, the receptor formerly

designated alpha 1a was renamed alpha 1d. The new nomenclature is used throughout this application. Stable cell lines expressing these alpha 1 receptor subtypes are referred to herein; however, these cell lines were deposited with the American Type Culture Collection (ATCC) under the old nomenclature. For a review of the classification of alpha 1 adrenoceptor subtypes,

see, Martin C. Michel, et al., Naunyn-Schmiedeberg's Arch. Pharmacol. (1995) 352:1-10.

The differences in the alpha adrenergic receptor subtypes have relevance in pathophysiologic conditions. Benign prostatic hyperplasia, also known as benign prostatic hypertrophy or BPH, is an illness typically affecting men over fifty years of age, increasing in severity with increasing age. The symptoms of the condition include, but are not limited to, increased difficulty in urination and sexual dysfunction. These symptoms are induced by enlargement, or hyperplasia, of the prostate gland. As the prostate increases in size, it impinges on free-flow of fluids through the male urethra. Concomitantly, the increased noradrenergic innervation of the enlarged prostate leads to an increased adrenergic tone of the bladder neck and urethra, further restricting the flow of urine through the urethra.

The .alpha..sub.2 receptors appear to have diverged rather early from either .beta. or .alpha..sub.1 receptors. The .alpha..sub.2 receptors have been broken down into 3 molecularly distinct subtypes termed .alpha..sub.2 C2, .alpha..sub.2 C4, and .alpha..sub.2 C10 based on their chromosomal location. These subtypes appear to correspond to the pharmacologically defined .alpha..sub.2B, .alpha..sub.2C, and .alpha..sub.2A subtypes, respectively (Bylund et al., 1992).

While all the receptors of the adrenergic type are recognized by epinephrine, they are pharmacologically distinct and are encoded by separate genes. These receptors are generally coupled to different second messenger pathways that are linked through G-proteins. Among the adrenergic receptors, .beta..sub.1 and .beta..sub.2 receptors activate the adenylate cyclase, .alpha..sub.2 receptors inhibit adenylate cyclase and .alpha..sub.1 receptors activate phospholipase C pathways, stimulating breakdown of polyphosphoinositides (Chung, F. Z. et al., J. Biol. Chem., 263:4052 (1988)). .alpha..sub.1 and .alpha..sub.2 adrenergic receptors differ in their cell activity for drugs.

Issued US patent that disclose the utility of members of this family of proteins include, but are not limited to, 6,063.785 Phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia; 6,060.492 Selective .beta.3 adrenergic agonists; 6,057.350 Alpha 1a adrenergic receptor antagonists; 6,046.192 Phenylethanolaminotetralincarboxamide derivatives; 6,046.183 Method of synergistic treatment for benign prostatic hyperplasia; 6,043.253 Fused piperidine substituted arylsulfonamides as .beta.3-agonists; 6,043.224 Compositions and

methods for treatment of neurological disorders and neurodegenerative diseases; 6.037.354 Alpha 1a adrenergic receptor antagonists; 6.034.106 Oxadiazole benzenesulfonamides as selective .beta..sub.3 Agonist for the treatment of Diabetes and Obesity; 6.011.048 Thiazole benzenesulfonamides as .beta.3 agonists for treatment of diabetes and obesity; 6.008.361 5 5.994.506 Adrenergic receptor; 5.994.294 Nitrosated and nitrosylated .alpha.-adrenergic receptor antagonist compounds, compositions and their uses; 5.990.128 .alpha..sub.1C specific compounds to treat benign prostatic hyperplasia; 5.977.154 Selective .beta.3 adrenergic agonist; 5.977.115 Alpha 1a adrenergic receptor antagonists; 5.939.443 Selective .beta.3 adrenergic agonists; 5.932.538 Nitrosated and nitrosylated .alpha.-adrenergic receptor antagonist 10 compounds, compositions and their uses; 5.922.722 Alpha 1a adrenergic receptor antagonists 26 5.908.830 and 5.861.309 DNA encoding human alpha 1 adrenergic receptors.

### Purinergic GPCRs

#### Purinoreceptor P2Y1

15 P2 purinoreceptors have been broadly classified as P2X receptors which are ATP-gated channels; P2Y receptors, a family of G protein-coupled receptors, and P2Z receptors, which mediate nonselective pores in mast cells. Numerous subtypes have been identified for each of the P2 receptor classes. P2Y receptors are characterized by their selective responsiveness towards ATP and its analogs. Some respond also to UTP. Based on the recommendation for nomenclature of P2 20 purinoreceptors, the P2Y purinoreceptors were numbered in the order of cloning. P2Y1, P2Y2 and P2Y3 have been cloned from a variety of species. P2Y1 responds to both ADP and ATP. Analysis of P2Y receptor subtype expression in human bone and 2 osteoblastic cell lines by RT-PCR showed that all known human P2Y receptor subtypes were expressed: P2Y1, P2Y2, P2Y4, P2Y6, and P2Y7 (Maier et al. 1997). In contrast, analysis of brain-derived cell lines suggested that a selective 25 expression of P2Y receptor subtypes occurs in brain tissue.

Leon et al. generated P2Y1-null mice to define the physiologic role of the P2Y1 receptor (J. Clin. Invest. 104: 1731-1737(1999)). These mice were viable with no apparent abnormalities affecting their development, survival, reproduction, or morphology of platelets, and the platelet count in these animals was identical to that of wildtype mice. However, platelets from P2Y1- 30 deficient mice were unable to aggregate in response to usual concentrations of ADP and displayed impaired aggregation to other agonists, while high concentrations of ADP induced platelet aggregation without shape change. In addition, ADP-induced inhibition of adenylyl cyclase still

occurred, demonstrating the existence of an ADP receptor distinct from P2Y1. P2Y1-null mice had no spontaneous bleeding tendency but were resistant to thromboembolism induced by intravenous injection of ADP or collagen and adrenaline. Hence, the P2Y1 receptor plays an essential role in thrombotic states and represents a potential target for antithrombotic drugs. Somers et al. mapped the P2RY1 gene between flanking markers D3S1279 and D3S1280 at a position 173 to 174 cM from the most telomeric markers on the short arm of chromosome 3. (Genomics 44: 127-130 (1997)).

#### Purinoceptor P2Y2

The chloride ion secretory pathway that is defective in cystic fibrosis (CF) can be bypassed by an alternative pathway for chloride ion transport that is activated by extracellular nucleotides. Accordingly, the P2 receptor that mediates this effect is a therapeutic target for improving chloride secretion in CF patients. Parr et al. reported the sequence and functional expression of a cDNA cloned from human airway epithelial cells that encodes a protein with properties of a P2Y nucleotide receptor. (Proc. Nat. Acad. Sci. 91: 3275-3279 (1994)) The human P2RY2 gene was mapped to chromosome 11q13.5-q14.1.

#### Purinoceptor P2RY4

The P2RY4 receptor appears to be activated specifically by UTP and UDP, but not by ATP and ADP. Activation of this uridine nucleotide receptor resulted in increased inositol phosphate formation and calcium mobilization. The UNR gene is located on chromosome Xq13.

#### Purinoceptor P2Y6

Somers et al. mapped the P2RY6 gene to 11q13.5, between polymorphic markers D11S1314 and D11S916, and P2RY2 maps within less than 4 cM of P2RY6. (Genomics 44: 127-130 (1997)) This was the first chromosomal clustering of this gene family to be described.

Adenine and uridine nucleotides, in addition to their well established role in intracellular energy metabolism, phosphorylation, and nucleic acid synthesis, also are important extracellular signaling molecules. P2Y metabotropic receptors are GPCRs that mediate the effects of extracellular nucleotides to regulate a wide variety of physiological processes. At least ten subfamilies of P2Y receptors have been identified. These receptor subfamilies differ greatly in their sequences and in their nucleotide agonist selectivities and efficacies.

It has been demonstrated that the P2Y1 receptors are strongly expressed in the brain, but the P2Y2, P2Y4 and P2Y6 receptors are also present. The localisation of one or more of these subtypes

on neurons, on glia cells, on brain vasculature or on ventricle ependimal cells was found by in situ mRNA hybridisation and studies on those cells in culture. The P2Y<sub>1</sub> receptors are prominent on neurons. The coupling of certain P2Y receptor subtypes to N-type Ca<sup>2+</sup> channels or to particular K<sup>+</sup> channels was also demonstrated.

5 It has also been demonstrated that several P2Y receptors mediate potent growth stimulatory effects on smooth muscle cells by stimulating intracellular pathways including Gq-proteins, protein kinase C and tyrosine phosphorylation, leading to increased immediate early gene expression, cell number, DNA and protein synthesis. It has been further demonstrated that P2Y regulation plays a mitogenic role in response to the development of atherosclerosis.

10 It has further been demonstrated that P2Y receptors play a critical role in cystic fibrosis. The volume and composition of the liquid that lines the airway surface is modulated by active transport of ions across the airway epithelium. This in turn is regulated both by autonomic agonists acting on basolateral receptors and by agonists acting on luminal receptors. Specifically, extracellular nucleotides present in the airway surface liquid act on luminal P2Y receptors to control  
15 both Cl<sup>-</sup> secretion and Na<sup>+</sup> absorption. Since nucleotides are released in a regulated manner from airway epithelial cells, it is likely that their control over airway ion transport forms part of an autocrine regulatory system localised to the luminal surface of airway epithelia. In addition to this physiological role, P2Y receptor agonists have the potential to be of crucial benefit in the treatment of CF, a disorder of epithelial ion transport. The airways of people with CF have defective Cl<sup>-</sup>  
20 secretion and abnormally high rates of Na<sup>+</sup> absorption. Since P2Y receptor agonists can regulate both these ion transport pathways they have the potential to pharmacologically bypass the ion transport defects in CF.

For a detailed description of a putative neurotransmitter GPCR involved in neurotransmitter signaling, see Zeng *et al.*, *Biochem. Biophys. Res. Commun.* 242 (3), 575-578 (1998).

25 GPCRs, particularly GPCRs involved in neurotransmitter signaling, are a major target for drug action and development. Accordingly, it is valuable to the field of pharmaceutical development to identify and characterize previously unknown GPCRs. The present invention advances the state of the art by providing a previously unidentified human GPCR.

## 30 SUMMARY OF THE INVENTION

The present invention is based in part on the identification of nucleic acid sequences that encode amino acid sequences of human GPCR peptides and proteins that are involved in cell

signaling, particularly neurotransmitter signaling, allelic variants thereof and other mammalian orthologs thereof. These unique peptide sequences, and nucleic acid sequences that encode these peptides, can be used as models for the development of human therapeutic targets, aid in the identification of therapeutic proteins, and serve as targets for the development of human

therapeutic agents.

The proteins of the present inventions are GPCRs that participate in signaling pathways, particularly neurotransmitter signaling pathways, in cells that express these proteins. Experimental data as provided in Figure 1 indicates expression in humans in the stomach, placenta, kidney, skeletal muscle, liver, bone marrow, and thymus. As used herein, a "signaling pathway" refers to the modulation (e.g., stimulation or inhibition) of a cellular function/activity upon the binding of a ligand to the GPCR protein. Examples of such functions include mobilization of intracellular molecules that participate in a signal transduction pathway, e.g., phosphatidylinositol 4,5-bisphosphate (PIP<sub>2</sub>), inositol 1,4,5-triphosphate (IP<sub>3</sub>) and adenylate cyclase; polarization of the plasma membrane; production or secretion of molecules; alteration in the structure of a cellular component; cell proliferation, e.g., synthesis of DNA; cell migration; cell differentiation; and cell survival

The response mediated by the receptor protein depends on the type of cell it is expressed on. Some information regarding the types of cells that express other members of the subfamily of GPCRs of the present invention is already known in the art (see references cited in Background and information regarding closest homologous protein provided in Figure 2; Experimental data as provided in Figure 1 indicates expression in humans in the stomach, placenta, kidney, skeletal muscle, liver, bone marrow, and thymus). For example, in some cells, binding of a ligand to the receptor protein may stimulate an activity such as release of compounds, gating of a channel, cellular adhesion, migration, differentiation, etc., through phosphatidylinositol or cyclic AMP metabolism and turnover while in other cells, the binding of the ligand will produce a different result. Regardless of the cellular activity/response modulated by the particular GPCR of the present invention, a skilled artisan will clearly know that the receptor protein is a GPCR and interacts with G proteins to produce one or more secondary signals, in a variety of intracellular signal transduction pathways, e.g., through phosphatidylinositol or cyclic AMP metabolism and turnover, in a cell thus participating in a biological process in the cells or tissues that express the GPCR. Experimental data as provided in Figure 1 indicates that GPCR proteins of the present invention are expressed in humans in the stomach, placenta, kidney, skeletal muscle, liver, bone marrow, and thymus. Specifically, a virtual northern blot shows expression in the stomach. In addition, PCR-based tissue

screening panels indicate expression in placenta, kidney, skeletal muscle, liver, bone marrow, and thymus tissue.

As used herein, "phosphatidylinositol turnover and metabolism" refers to the molecules involved in the turnover and metabolism of phosphatidylinositol 4,5-bisphosphate (PIP<sub>2</sub>) as well as to the activities of these molecules. PIP<sub>2</sub> is a phospholipid found in the cytosolic leaflet of the plasma membrane. Binding of ligand to the receptor activates, in some cells, the plasma-membrane enzyme phospholipase C that in turn can hydrolyze PIP<sub>2</sub> to produce 1,2-diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP<sub>3</sub>). Once formed IP<sub>3</sub> can diffuse to the endoplasmic reticulum surface where it can bind an IP<sub>3</sub> receptor, e.g., a calcium channel protein containing an IP<sub>3</sub> binding site. IP<sub>3</sub> binding can induce opening of the channel, allowing calcium ions to be released into the cytoplasm. IP<sub>3</sub> can also be phosphorylated by a specific kinase to form inositol 1,3,4,5-tetraphosphate (IP<sub>4</sub>), a molecule that can cause calcium entry into the cytoplasm from the extracellular medium. IP<sub>3</sub> and IP<sub>4</sub> can subsequently be hydrolyzed very rapidly to the inactive products inositol 1,4-bisphosphate (IP<sub>2</sub>) and inositol 1,3,4-triphosphate, respectively. These inactive products can be recycled by the cell to synthesize PIP<sub>2</sub>. The other second messenger produced by the hydrolysis of PIP<sub>2</sub>, namely 1,2-diacylglycerol (DAG), remains in the cell membrane where it can serve to activate the enzyme protein kinase C. Protein kinase C is usually found soluble in the cytoplasm of the cell, but upon an increase in the intracellular calcium concentration, this enzyme can move to the plasma membrane where it can be activated by DAG. The activation of protein kinase C in different cells results in various cellular responses such as the phosphorylation of glycogen synthase, or the phosphorylation of various transcription factors, e.g., NF- $\kappa$ B. The language "phosphatidylinositol activity", as used herein, refers to an activity of PIP<sub>2</sub> or one of its metabolites.

Another signaling pathway in which the receptor may participate is the cAMP turnover pathway. As used herein, "cyclic AMP turnover and metabolism" refers to the molecules involved in the turnover and metabolism of cyclic AMP (cAMP) as well as to the activities of these molecules. Cyclic AMP is a second messenger produced in response to ligand-induced stimulation of certain G protein coupled receptors. In the cAMP signaling pathway, binding of a ligand to a GPCR can lead to the activation of the enzyme adenylyl cyclase, which catalyzes the synthesis of cAMP. The newly synthesized cAMP can in turn activate a cAMP-dependent protein kinase. This activated kinase can phosphorylate a voltage-gated potassium channel protein, or an associated protein, and lead to the inability of the potassium channel to open during an action potential. The inability of the potassium channel to open results in a decrease in the outward flow of potassium, which normally repolarizes the membrane of a neuron, leading to

prolonged membrane depolarization.

By targeting an agent to modulate a GPCR, the signaling activity and biological process mediated by the receptor can be agonized or antagonized in specific cells and tissues.

Experimental data as provided in Figure 1 indicates expression in humans in the stomach,

- 5 placenta, kidney, skeletal muscle, liver, bone marrow, and thymus. Such agonism and antagonism serves as a basis for modulating a biological activity in a therapeutic context (mammalian therapy) or toxic context (anti-cell therapy, e.g. anti-cancer agent).

## DESCRIPTION OF THE FIGURE SHEETS

- 10 FIGURE 1 provides the nucleotide sequence of a cDNA molecule that encodes the GPCR of the present invention. (SEQ ID NO:1) In addition, structure and functional information is provided, such as ATG start, stop and tissue distribution, where available, that allows one to readily determine specific uses of inventions based on this molecular sequence. Experimental data as provided in Figure 1 indicates expression in humans in the stomach, placenta, kidney,
- 15 skeletal muscle, liver, bone marrow, and thymus.

FIGURE 2 provides the predicted amino acid sequence of the GPCR of the present invention. (SEQ ID NO:2) In addition structure and functional information such as protein family, function, and modification sites is provided where available, allowing one to readily determine specific uses of inventions based on this molecular sequence.

- 20 FIGURE 3 provides genomic sequences that span the gene encoding the GPCR protein of the present invention. (SEQ ID NO:3) In addition, structure and functional information, such as intron/exon structure, promoter location, etc., is provided where available, allowing one to readily determine specific uses of inventions based on this molecular sequence. As illustrated in Figure 3, G1711T is a known SNP variant.

25

## DETAILED DESCRIPTION OF THE INVENTION

### General Description

- The present invention is based on the sequencing of the human genome. During the sequencing and assembly of the human genome, analysis of the sequence information revealed
- 30 previously unidentified fragments of the human genome that encode peptides that share structural and/or sequence homology to protein/peptide/domains identified and characterized

within the art as being a GPCR protein or part of a GPCR protein, that are involved in cell signaling, particularly neurotransmitter signaling. Utilizing these sequences, additional genomic sequences were assembled and transcript and/or cDNA sequences were isolated and characterized. Based on this analysis, the present invention provides amino acid sequences of human GPCR peptides and proteins that are involved in cell signaling, particularly neurotransmitter signaling, nucleic acid sequences in the form of transcript sequences, cDNA sequences and/or genomic sequences that encode these GPCR peptides and proteins, nucleic acid variation (allelic information), tissue distribution of expression, and information about the closest art known protein/peptide/domain that has structural or sequence homology to the GPCR of the present invention.

In addition to being previously unknown, the peptides that are provided in the present invention are selected based on their ability to be used for the development of commercially important products and services. Specifically, the present peptides are selected based on homology and/or structural relatedness to known GPCR proteins involved in cell signaling, particularly neurotransmitter signaling, and the expression pattern observed. Experimental data as provided in Figure 1 indicates expression in humans in the stomach, placenta, kidney, skeletal muscle, liver, bone marrow, and thymus. The art has clearly established the commercial importance of members of this family of proteins and proteins that have expression patterns similar to that of the present gene. Some of the more specific features of the peptides of the present invention, and the uses thereof, are described herein, particularly in the Background of the Invention and in the annotation provided in the Figures, and/or are known within the art for each of the known GPCR proteins involved in cell signaling, particularly neurotransmitter signaling.

## Specific Embodiments

### Peptide Molecules

The present invention provides nucleic acid sequences that encode protein molecules that have been identified as being members of the GPCR family of proteins and are involved in cell signaling, particularly neurotransmitter signaling (protein sequences are provided in Figure 2, cDNA sequences are provided in Figure 1 and genomic sequences are provided in Figure 3). The peptide sequences provided in Figure 2, as well as the obvious variants described herein, particularly allelic variants as identified herein and using the information in Figure 3, will be

referred herein as the GPCR peptides of the present invention, GPCR peptides, or peptides/proteins of the present invention.

The present invention provides isolated peptide and protein molecules that consist of, consist essentially of, or comprise the amino acid sequences of the GPCR peptides disclosed in Figure 2, (encoded by the nucleic acid molecule shown in Figure 1, cDNA sequence, or Figure 3, genomic sequence), as well as all obvious variants of these peptides that are within the art to make and use. Some of these variants are described in detail below.

As used herein, a peptide is said to be "isolated" or "purified" when it is substantially free of cellular material or free of chemical precursors or other chemicals. The peptides of the present invention can be purified to homogeneity or other degrees of purity. The level of purification will be based on the intended use. The critical feature is that the preparation allows for the desired function of the peptide, even if in the presence of considerable amounts of other components (the features of an isolated nucleic acid molecule is discussed below).

In some uses, "substantially free of cellular material" includes preparations of the peptide having less than about 30% (by dry weight) other proteins (i.e., contaminating protein), less than about 20% other proteins, less than about 10% other proteins, or less than about 5% other proteins. When the peptide is recombinantly produced, it can also be substantially free of culture medium, i.e., culture medium represents less than about 20% of the volume of the protein preparation.

The language "substantially free of chemical precursors or other chemicals" includes preparations of the peptide in which it is separated from chemical precursors or other chemicals that are involved in its synthesis. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of the GPCR peptide having less than about 30% (by dry weight) chemical precursors or other chemicals, less than about 20% chemical precursors or other chemicals, less than about 10% chemical precursors or other chemicals, or less than about 5% chemical precursors or other chemicals.

The isolated GPCR peptide can be purified from cells that naturally express it, purified from cells that have been altered to express it (recombinant), or synthesized using known protein synthesis methods. Experimental data as provided in Figure 1 indicates expression in humans in the stomach, placenta, kidney, skeletal muscle, liver, bone marrow, and thymus. For example, a nucleic acid molecule encoding the GPCR peptide is cloned into an expression vector, the expression vector introduced into a host cell and the protein expressed in the host cell. The protein can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques. Many of these techniques are described in detail below.

Accordingly, the present invention provides proteins that consist of the amino acid sequences provided in Figure 2 (SEQ ID NO:2), for example, proteins encoded by the cDNA nucleic acid sequences shown in Figure 1 (SEQ ID NO:1) and the genomic sequences provided in Figure 3 (SEQ ID NO:3). The amino acid sequence of such a protein is provided in Figure 2. A protein consists of an amino acid sequence when the amino acid sequence is the final amino acid sequence of the protein.

The present invention further provides proteins that consist essentially of the amino acid sequences provided in Figure 2 (SEQ ID NO:2), for example, proteins encoded by the cDNA nucleic acid sequences shown in Figure 1 (SEQ ID NO:1) and the genomic sequences provided in Figure 3 (SEQ ID NO:3). A protein consists essentially of an amino acid sequence when such an amino acid sequence is present with only a few additional amino acid residues, for example from about 1 to about 100 or so additional residues, typically from 1 to about 20 additional residues in the final protein.

The present invention further provides proteins that comprise the amino acid sequences provided in Figure 2 (SEQ ID NO:2), for example, proteins encoded by the cDNA nucleic acid sequences shown in Figure 1 (SEQ ID NO:1) and the genomic sequences provided in Figure 3 (SEQ ID NO:3). A protein comprises an amino acid sequence when the amino acid sequence is at least part of the final amino acid sequence of the protein. In such a fashion, the protein can be only the peptide or have additional amino acid molecules, such as amino acid residues (contiguous encoded sequence) that are naturally associated with it or heterologous amino acid residues/peptide sequences. Such a protein can have a few additional amino acid residues or can comprise several hundred or more additional amino acids. The preferred classes of proteins that are comprised of the GPCR peptides of the present invention are the naturally occurring mature proteins. A brief description of how various types of these proteins can be made/isolated is provided below.

The GPCR peptides of the present invention can be attached to heterologous sequences to form chimeric or fusion proteins. Such chimeric and fusion proteins comprise a GPCR peptide operatively linked to a heterologous protein having an amino acid sequence not substantially homologous to the GPCR peptide. "Operatively linked" indicates that the GPCR peptide and the heterologous protein are fused in-frame. The heterologous protein can be fused to the N-terminus or C-terminus of the GPCR peptide.

In some uses, the fusion protein does not affect the activity of the GPCR peptide *per se*. For example, the fusion protein can include, but is not limited to, enzymatic fusion proteins, for example beta-galactosidase fusions, yeast two-hybrid GAL fusions, poly-His fusions, MYC-tagged, HI-

tagged and Ig fusions. Such fusion proteins, particularly poly-His fusions, can facilitate the purification of recombinant GPCR peptide. In certain host cells (e.g., mammalian host cells), expression and/or secretion of a protein can be increased by using a heterologous signal sequence.

A chimeric or fusion protein can be produced by standard recombinant DNA techniques.

5 For example, DNA fragments coding for the different protein sequences are ligated together in-frame in accordance with conventional techniques. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be  
10 annealed and re-amplified to generate a chimeric gene sequence (see Ausubel *et al.*, *Current Protocols in Molecular Biology*, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST protein). A GPCR peptide-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the GPCR peptide.

15 As mentioned above, the present invention also provides and enables obvious variants of the amino acid sequence of the proteins of the present invention, such as naturally occurring mature forms of the peptide, allelic/sequence variants of the peptides, non-naturally occurring recombinantly derived variants of the peptides, and orthologs and paralogs of the peptides. Such variants can readily be generated using art-known techniques in the fields of recombinant nucleic  
20 acid technology and protein biochemistry. It is understood, however, that variants exclude any amino acid sequences disclosed prior to the invention.

Such variants can readily be identified/made using molecular techniques and the sequence information disclosed herein. Further, such variants can readily be distinguished from other peptides based on sequence and/or structural homology to the GPCR peptides of the present  
25 invention. The degree of homology/identity present will be based primarily on whether the peptide is a functional variant or non-functional variant, the amount of divergence present in the paralog family and the evolutionary distance between the orthologs.

To determine the percent identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be  
30 introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% or more of the length of the reference sequence.

The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

The comparison of sequences and determination of percent identity and similarity between two sequences can be accomplished using a mathematical algorithm. (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data, Part I*, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (*J. Mol. Biol.* (48):444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at <http://www.gcg.com>), using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (Devereux, J., *et al.*, *Nucleic Acids Res.* 12(1):387 (1984)) (available at <http://www.gcg.com>), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In another embodiment, the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of E. Meyers and W. Miller (*CABIOS*, 4:11-17 (1989)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

The nucleic acid and protein sequences of the present invention can further be used as a "query sequence" to perform a search against sequence databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (*J. Mol. Biol.* 215:403-10 (1990)). BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12

to obtain nucleotide sequences homologous to the nucleic acid molecules of the invention.

BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to the proteins of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (*Nucleic Acids Res.* 25(17):3389-3402 (1997)). When utilizing BLAST and gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.

Full-length pre-processed forms, as well as mature processed forms, of proteins that comprise one of the peptides of the present invention can readily be identified as having complete sequence identity to one of the GPCR peptides of the present invention as well as being encoded by the same genetic locus as the GPCR peptide provided herein. As indicated by the data presented in Figure 3, the map position was determined to be on chromosome 6 by radiation hybrid mapping.

Allelic variants of a GPCR peptide can readily be identified as being a human protein having a high degree (significant) of sequence homology/identity to at least a portion of the GPCR peptide as well as being encoded by the same genetic locus as the GPCR peptide provided herein. Genetic locus can readily be determined based on the genomic information provided in Figure 3, such as the genomic sequence mapped to the reference human. As indicated by the data presented in Figure 3, the map position was determined to be on chromosome 6 by radiation hybrid mapping. As used herein, two proteins (or a region of the proteins) have significant homology when the amino acid sequences are typically at least about 70-80%, 80-90%, and more typically at least about 90-95% or more homologous. A significantly homologous amino acid sequence, according to the present invention, will be encoded by a nucleic acid sequence that will hybridize to a GPCR peptide encoding nucleic acid molecule under stringent conditions as more fully described below.

Figure 3 provides information on a SNP variant, G1711T, which has been found in a gene encoding the GPCR protein of the present invention. The change in the amino acid sequence caused by this SNP is indicated in Figure 3 and can readily be determined using the universal genetic code and the protein sequence provided in Figure 2 as a reference.

Paralogs of a GPCR peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of the GPCR peptide, as being encoded by a gene from humans, and as having similar activity or function. Two proteins will typically be considered paralogs when the amino acid sequences are typically at least about 60% or greater, and more typically at least about 70% or greater homology through a given region or domain. Such

paralogs will be encoded by a nucleic acid sequence that will hybridize to a GPCR peptide encoding nucleic acid molecule under moderate to stringent conditions as more fully described below.

Orthologs of a GPCR peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of the GPCR peptide as well as being encoded by a gene from another organism. Preferred orthologs will be isolated from mammals, preferably primates, for the development of human therapeutic targets and agents. Such orthologs will be encoded by a nucleic acid sequence that will hybridize to a GPCR peptide encoding nucleic acid molecule under moderate to stringent conditions, as more fully described below, depending on the degree of relatedness of the two organisms yielding the proteins.

Non-naturally occurring variants of the GPCR peptides of the present invention can readily be generated using recombinant techniques. Such variants include, but are not limited to deletions, additions and substitutions in the amino acid sequence of the GPCR peptide. For example, one class of substitutions are conserved amino acid substitution. Such substitutions are those that substitute a given amino acid in a GPCR peptide by another amino acid of like characteristics. Typically seen as conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu, and Ile; interchange of the hydroxyl residues Ser and Thr; exchange of the acidic residues Asp and Glu; substitution between the amide residues Asn and Gln; exchange of the basic residues Lys and Arg; and replacements among the aromatic residues Phe and Tyr. Guidance concerning which amino acid changes are likely to be phenotypically silent are found in Bowie *et al.*, *Science* 247:1306-1310 (1990).

Variant GPCR peptides can be fully functional or can lack function in one or more activities, e.g. ability to bind ligand, ability to bind G-protein, ability to mediate signaling, etc. Fully functional variants typically contain only conservative variation or variation in non-critical residues or in non-critical regions. Figure 2 provides the result of protein analysis that identifies critical domains/regions. Functional variants can also contain substitution of similar amino acids that result in no change or an insignificant change in function. Alternatively, such substitutions may positively or negatively affect function to some degree.

Non-functional variants typically contain one or more non-conservative amino acid substitutions, deletions, insertions, inversions, or truncation or a substitution, insertion, inversion, or deletion in a critical residue or critical region.

Amino acids that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham *et al.*, *Science*

244:1081-1085 (1989)), particularly using the results provided in Figure 2. The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity such as ligand/effector molecule binding or in assays such as an *in vitro* proliferative activity. Sites that are critical for ligand-receptor binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith *et al.*, *J. Mol. Biol.* 224:899-904 (1992); de Vos *et al.* *Science* 255:306-312 (1992)).

The present invention further provides fragments of the GPCR peptides, in addition to proteins and peptides that comprise and consist of such fragments, particularly those comprising the residues identified in Figure 2. The fragments to which the invention pertains, however, are not to be construed as encompassing fragments that may be disclosed publicly prior to the present invention.

As used herein, a fragment comprises at least 8, 10, 12, 14, 16, or more contiguous amino acid residues from a GPCR peptide. Such fragments can be chosen based on the ability to retain one or more of the biological activities of the GPCR peptide or could be chosen for the ability to perform a function, e.g. ability to bind ligand or effector molecule or act as an immunogen. Particularly important fragments are biologically active fragments, peptides which are, for example, about 8 or more amino acids in length. Such fragments will typically comprise a domain or motif of the GPCR peptide, e.g., active site, a G-protein binding site, a transmembrane domain or a ligand-binding domain. Further, possible fragments include, but are not limited to, domain or motif containing fragments, soluble peptide fragments, and fragments containing immunogenic structures. Predicted domains and functional sites are readily identifiable by computer programs well-known and readily available to those of skill in the art (e.g., PROSITE analysis). The results of one such analysis are provided in Figure 2.

Polypeptides often contain amino acids other than the 20 amino acids commonly referred to as the 20 naturally occurring amino acids. Further, many amino acids, including the terminal amino acids, may be modified by natural processes, such as processing and other post-translational modifications, or by chemical modification techniques well known in the art. Common modifications that occur naturally in GPCR peptides are described in basic texts, detailed monographs, and the research literature, and they are well known to those of skill in the art (some of these features are identified in Figure 2).

Known modifications include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety,

covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

Such modifications are well-known to those of skill in the art and have been described in great detail in the scientific literature. Several particularly common modifications, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, for instance, are described in most basic texts, such as *Proteins - Structure and Molecular Properties*, 2nd Ed., T.E. Creighton, W. H. Freeman and Company, New York (1993). Many detailed reviews are available on this subject, such as by Wold, F., *Posttranslational Covalent Modification of Proteins*, B.C. Johnson, Ed., Academic Press, New York 1-12 (1983); Seifter *et al.* (*Meth. Enzymol.* 182: 626-646 (1990)) and Rattan *et al.* (*Ann. N.Y. Acad. Sci.* 663:48-62 (1992)).

Accordingly, the GPCR peptides of the present invention also encompass derivatives or analogs in which a substituted amino acid residue is not one encoded by the genetic code, in which a substituent group is included, in which the mature GPCR peptide is fused with another compound, such as a compound to increase the half-life of the GPCR peptide (for example, polyethylene glycol), or in which the additional amino acids are fused to the mature GPCR peptide, such as a leader or secretory sequence or a sequence for purification of the mature GPCR peptide or a pro-protein sequence.

#### Protein/Peptide Uses

The proteins of the present invention can be used in substantial and specific assays related to the functional information provided in the Figures and Back Ground Section; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its binding partner or receptor) in biological fluids; and as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state). Where the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the protein can be used to identify

the binding partner so as to develop a system to identify inhibitors of the binding interaction. Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as commercial products.

Methods for performing the uses listed above are well known to those skilled in the art.

- 5 References disclosing such methods include "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E. F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S. L. and A. R. Kimmel eds., 1987.

- 10 The potential uses of the peptides of the present invention are based primarily on the source of the protein as well as the class/action of the protein. For example, GPCRs isolated from humans and their human/mammalian orthologs serve as targets for identifying agents for use in mammalian therapeutic applications, e.g. a human drug, particularly in modulating a biological or pathological response in a cell or tissue that expresses the GPCR. Experimental data as provided in Figure 1 indicates that GPCR proteins of the present invention are expressed
- 15 in humans in the stomach, placenta, kidney, skeletal muscle, liver, bone marrow, and thymus. Specifically, a virtual northern blot shows expression in the stomach. In addition, PCR-based tissue screening panels indicate expression in placenta, kidney, skeletal muscle, liver, bone marrow, and thymus tissue. Approximately 70% of all pharmaceutical agents modulate the activity of a GPCR. A combination of the invertebrate and mammalian ortholog can be used in
- 20 selective screening methods to find agents specific for invertebrates. The structural and functional information provided in the Background and Figures provide specific and substantial uses for the molecules of the present invention, particularly in combination with the expression information provided in Figure 1. Experimental data as provided in Figure 1 indicates expression in humans in the stomach, placenta, kidney, skeletal muscle, liver, bone marrow, and thymus.
- 25 Such uses can readily be determined using the information provided herein, that known in the art and routine experimentation.

- The proteins of the present invention (including variants and fragments that may have been disclosed prior to the present invention) are useful for biological assays related to GPCRs that are involved in cell signaling, particularly neurotransmitter signaling. Such assays involve any of the
- 30 known GPCR functions or activities or properties useful for diagnosis and treatment of GPCR-related conditions that are specific for the subfamily of GPCRs that the one of the present invention belongs to, particularly in cells and tissues that express this receptor. Experimental data as provided in Figure 1 indicates that GPCR proteins of the present invention are expressed in humans in the

stomach, placenta, kidney, skeletal muscle, liver, bone marrow, and thymus. Specifically, a virtual northern blot shows expression in the stomach. In addition, PCR-based tissue screening panels indicate expression in placenta, kidney, skeletal muscle, liver, bone marrow, and thymus tissue.

The proteins of the present invention are also useful in drug screening assays, in cell-based or cell-free systems. Cell-based systems can be native, i.e., cells that normally express the receptor protein, as a biopsy or expanded in cell culture. Experimental data as provided in Figure 1 indicates expression in humans in the stomach, placenta, kidney, skeletal muscle, liver, bone marrow, and thymus. In an alternate embodiment, cell-based assays involve recombinant host cells expressing the receptor protein.

The polypeptides can be used to identify compounds that modulate receptor activity of the protein in its natural state, or an altered form that causes a specific disease or pathology associated with the receptor. Both the GPCRs of the present invention and appropriate variants and fragments can be used in high-throughput screens to assay candidate compounds for the ability to bind to the receptor. These compounds can be further screened against a functional receptor to determine the effect of the compound on the receptor activity. Further, these compounds can be tested in animal or invertebrate systems to determine activity/effectiveness. Compounds can be identified that activate (agonist) or inactivate (antagonist) the receptor to a desired degree.

Further, the proteins of the present invention can be used to screen a compound for the ability to stimulate or inhibit interaction between the receptor protein and a molecule that normally interacts with the receptor protein, e.g. a ligand or a component of the signal pathway that the receptor protein normally interacts (for example, a G-protein or other interactor involved in cAMP or phosphatidylinositol turnover and/or adenylate cyclase, or phospholipase C activation). Such assays typically include the steps of combining the receptor protein with a candidate compound under conditions that allow the receptor protein, or fragment, to interact with the target molecule, and to detect the formation of a complex between the protein and the target or to detect the biochemical consequence of the interaction with the receptor protein and the target, such as any of the associated effects of signal transduction such as G-protein phosphorylation, cAMP or phosphatidylinositol turnover, and adenylate cyclase or phospholipase C activation.

Candidate compounds include, for example, 1) peptides such as soluble peptides, including Ig-tailed fusion peptides and members of random peptide libraries (see, e.g., Lam *et al.*, *Nature* 354:82-84 (1991); Houghten *et al.*, *Nature* 354:84-86 (1991)) and combinatorial chemistry-derived molecular libraries made of D- and/or L- configuration amino acids; 2) phosphopeptides (e.g., members of random and partially degenerate, directed phosphopeptide libraries, see, e.g., Songyang

*et al.*, *Cell* 72:767-778 (1993)); 3) antibodies (e.g., polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, and single chain antibodies as well as Fab, F(ab')<sub>2</sub>, Fab expression library fragments, and epitope-binding fragments of antibodies); and 4) small organic and inorganic molecules (e.g., molecules obtained from combinatorial and natural product libraries).

5 One candidate compound is a soluble fragment of the receptor that competes for ligand binding. Other candidate compounds include mutant receptors or appropriate fragments containing mutations that affect receptor function and thus compete for ligand. Accordingly, a fragment that competes for ligand, for example with a higher affinity, or a fragment that binds ligand but does not allow release, is encompassed by the invention.

10 The invention further includes other end point assays to identify compounds that modulate (stimulate or inhibit) receptor activity. The assays typically involve an assay of events in the signal transduction pathway that indicate receptor activity. Thus, a cellular process such as proliferation, the expression of genes that are up- or down-regulated in response to the receptor protein dependent signal cascade, can be assayed. In one embodiment, the regulatory region of such genes can be  
15 operably linked to a marker that is easily detectable, such as luciferase.

Any of the biological or biochemical functions mediated by the receptor can be used as an endpoint assay. These include all of the biochemical or biochemical/biological events described herein, in the references cited herein, incorporated by reference for these endpoint assay targets, and other functions known to those of ordinary skill in the art or that can be readily identified using the  
20 information provided in the Figures, particularly Figure 2. Specifically, a biological function of a cell or tissues that expresses the receptor can be assayed. Experimental data as provided in Figure 1 indicates that GPCR proteins of the present invention are expressed in humans in the stomach, placenta, kidney, skeletal muscle, liver, bone marrow, and thymus. Specifically, a virtual northern blot shows expression in the stomach. In addition, PCR-based tissue screening panels indicate  
25 expression in placenta, kidney, skeletal muscle, liver, bone marrow, and thymus tissue.

Binding and/or activating compounds can also be screened by using chimeric receptor proteins in which the amino terminal extracellular domain, or parts thereof, the entire transmembrane domain or subregions, such as any of the seven transmembrane segments or any of the intracellular or extracellular loops and the carboxy terminal intracellular domain, or parts  
30 thereof, can be replaced by heterologous domains or subregions. For example, a G-protein-binding region can be used that interacts with a different G-protein than that which is recognized by the native receptor. Accordingly, a different set of signal transduction components is available as an end-point assay for activation. Alternatively, the entire transmembrane portion or subregions (such

as transmembrane segments or intracellular or extracellular loops) can be replaced with the entire transmembrane portion or subregions specific to a host cell that is different from the host cell from which the amino terminal extracellular domain and/or the G-protein-binding region are derived. This allows for assays to be performed in other than the specific host cell from which the receptor is derived. Alternatively, the amino terminal extracellular domain (and/or other ligand-binding regions) could be replaced by a domain (and/or other binding region) binding a different ligand, thus, providing an assay for test compounds that interact with the heterologous amino terminal extracellular domain (or region) but still cause signal transduction. Finally, activation can be detected by a reporter gene containing an easily detectable coding region operably linked to a transcriptional regulatory sequence that is part of the native signal transduction pathway.

The proteins of the present invention are also useful in competition binding assays in methods designed to discover compounds that interact with the receptor. Thus, a compound is exposed to a receptor polypeptide under conditions that allow the compound to bind or to otherwise interact with the polypeptide (Hodgson, Bio/technology, 1992, Sept 10(9);973-80). Soluble receptor polypeptide is also added to the mixture. If the test compound interacts with the soluble receptor polypeptide, it decreases the amount of complex formed or activity from the receptor target. This type of assay is particularly useful in cases in which compounds are sought that interact with specific regions of the receptor. Thus, the soluble polypeptide that competes with the target receptor region is designed to contain peptide sequences corresponding to the region of interest.

To perform cell free drug screening assays, it is sometimes desirable to immobilize either the receptor protein, or fragment, or its target molecule to facilitate separation of complexes from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay.

Techniques for immobilizing proteins on matrices can be used in the drug screening assays. In one embodiment, a fusion protein can be provided which adds a domain that allows the protein to be bound to a matrix. For example, glutathione-S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with the cell lysates (e.g.,  $^{35}\text{S}$ -labeled) and the candidate compound, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads are washed to remove any unbound label, and the matrix immobilized and radiolabel determined directly, or in the supernatant after the complexes are dissociated. Alternatively, the complexes can be dissociated from the matrix, separated by SDS-PAGE, and the level of receptor-binding protein found in the

bead fraction quantitated from the gel using standard electrophoretic techniques. For example, either the polypeptide or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin using techniques well known in the art. Alternatively, antibodies reactive with the protein but which do not interfere with binding of the protein to its target molecule can be derivatized to the wells of the plate, and the protein trapped in the wells by antibody conjugation. Preparations of a receptor-binding protein and a candidate compound are incubated in the receptor protein-presenting wells and the amount of complex trapped in the well can be quantitated. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the receptor protein target molecule, or which are reactive with receptor protein and compete with the target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the target molecule.

Agents that modulate one of the GPCRs of the present invention can be identified using one or more of the above assays, alone or in combination. It is generally preferable to use a cell-based or cell free system first and then confirm activity in an animal or other model system. Such model systems are well known in the art and can readily be employed in this context.

Modulators of receptor protein activity identified according to these drug screening assays can be used to treat a subject with a disorder mediated by the receptor pathway, by treating cells or tissues that express the GPCR. Experimental data as provided in Figure 1 indicates expression in humans in the stomach, placenta, kidney, skeletal muscle, liver, bone marrow, and thymus. These methods of treatment include the steps of administering a modulator of the GPCR's activity in a pharmaceutical composition to a subject in need of such treatment, the modulator being identified as described herein.

In yet another aspect of the invention, the GPCR proteins can be used as "bait proteins" in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Patent No. 5,283,317; Zervos et al. (1993) *Cell* 72:223-232; Madura et al. (1993) *J. Biol. Chem.* 268:12046-12054; Bartel et al. (1993) *Biotechniques* 14:920-924; Iwabuchi et al. (1993) *Oncogene* 8:1693-1696; and Brent WO94/10300), to identify other proteins, which bind to or interact with the GPCR and are involved in GPCR activity. Such GPCR-binding proteins are also likely to be involved in the propagation of signals by the GPCR proteins or GPCR targets as, for example, downstream elements of a GPCR-mediated signaling pathway. Alternatively, such GPCR-binding proteins are likely to be GPCR inhibitors.

The two-hybrid system is based on the modular nature of most transcription factors.

which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for a GPCR protein is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming a GPCR-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the GPCR protein.

This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an agent identified as described herein (e.g., a GPCR modulating agent, an antisense GPCR nucleic acid molecule, a GPCR-specific antibody, or a GPCR-binding partner) can be used in an animal or other model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal or other model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.

The GPCR proteins of the present invention are also useful to provide a target for diagnosing a disease or predisposition to disease mediated by the peptide. Accordingly, the invention provides methods for detecting the presence, or levels of, the protein (or encoding mRNA) in a cell, tissue, or organism. Experimental data as provided in Figure 1 indicates expression in humans in the stomach, placenta, kidney, skeletal muscle, liver, bone marrow, and thymus. The method involves contacting a biological sample with a compound capable of interacting with the receptor protein such that the interaction can be detected. Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

One agent for detecting a protein in a sample is an antibody capable of selectively binding to protein. A biological sample includes tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject.

The peptides of the present invention also provide targets for diagnosing active protein

activity, disease, or predisposition to disease, in a patient having a variant peptide, particularly activities and conditions that are known for other members of the family of proteins to which the present one belongs. Thus, the peptide can be isolated from a biological sample and assayed for the presence of a genetic mutation that results in aberrant peptide. This includes amino acid

5 substitution, deletion, insertion, rearrangement, (as the result of aberrant splicing events), and inappropriate post-translational modification. Analytic methods include altered electrophoretic mobility, altered tryptic peptide digest, altered receptor activity in cell-based or cell-free assay, alteration in ligand or antibody-binding pattern, altered isoelectric point, direct amino acid sequencing, and any other of the known assay techniques useful for detecting mutations in a protein.

10 Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

*In vitro* techniques for detection of peptide include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence using a detection reagent, such as an antibody or protein binding agent. Alternatively, the peptide can be detected *in vivo* in a  
15 subject by introducing into the subject a labeled anti-peptide antibody or other types of detection agent. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques. Particularly useful are methods that detect the allelic variant of a peptide expressed in a subject and methods which detect fragments of a peptide in a sample.

20 The peptides are also useful in pharmacogenomic analysis. Pharmacogenomics deal with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, e.g., Eichelbaum, M. (*Clin. Exp. Pharmacol. Physiol.* 23(10-11):983-985 (1996)), and Linder, M.W. (*Clin. Chem.* 43(2):254-266 (1997)). The clinical outcomes of these variations result in severe toxicity of therapeutic drugs in certain individuals or  
25 therapeutic failure of drugs in certain individuals as a result of individual variation in metabolism. Thus, the genotype of the individual can determine the way a therapeutic compound acts on the body or the way the body metabolizes the compound. Further, the activity of drug metabolizing enzymes effects both the intensity and duration of drug action. Thus, the pharmacogenomics of the individual permit the selection of effective compounds and effective dosages of such compounds for  
30 prophylactic or therapeutic treatment based on the individual's genotype. The discovery of genetic polymorphisms in some drug metabolizing enzymes has explained why some patients do not obtain the expected drug effects, show an exaggerated drug effect, or experience serious toxicity from standard drug dosages. Polymorphisms can be expressed in the phenotype of the extensive

metabolizer and the phenotype of the poor metabolizer. Accordingly, genetic polymorphism may lead to allelic protein variants of the receptor protein in which one or more of the receptor functions in one population is different from those in another population. The peptides thus allow a target to ascertain a genetic predisposition that can affect treatment modality. Thus, in a ligand-based treatment, polymorphism may give rise to amino terminal extracellular domains and/or other ligand-binding regions that are more or less active in ligand binding, and receptor activation. Accordingly, ligand dosage would necessarily be modified to maximize the therapeutic effect within a given population containing a polymorphism. As an alternative to genotyping, specific polymorphic peptides could be identified.

The peptides are also useful for treating a disorder characterized by an absence of, inappropriate, or unwanted expression of the protein. Experimental data as provided in Figure 1 indicates expression in humans in the stomach, placenta, kidney, skeletal muscle, liver, bone marrow, and thymus. Accordingly, methods for treatment include the use of the GPCR protein or fragments.

#### Antibodies

The invention also provides antibodies that selectively bind to one of the peptides of the present invention, a protein comprising such a peptide, as well as variants and fragments thereof. As used herein, an antibody selectively binds a target peptide when it binds the target peptide and does not significantly bind to unrelated proteins. An antibody is still considered to selectively bind a peptide even if it also binds to other proteins that are not substantially homologous with the target peptide so long as such proteins share homology with a fragment or domain of the peptide target of the antibody. In this case, it would be understood that antibody binding to the peptide is still selective despite some degree of cross-reactivity.

As used herein, an antibody is defined in terms consistent with that recognized within the art: they are multi-subunit proteins produced by a mammalian organism in response to an antigen challenge. The antibodies of the present invention include polyclonal antibodies and monoclonal antibodies, as well as fragments of such antibodies, including, but not limited to, Fab or F(ab')<sub>2</sub>, and Fv fragments.

Many methods are known for generating and/or identifying antibodies to a given target peptide. Several such methods are described by Harlow, Antibodies, Cold Spring Harbor Press. (1989).

In general, to generate antibodies, an isolated peptide is used as an immunogen and is administered to a mammalian organism, such as a rat, rabbit or mouse. The full-length protein, an antigenic peptide fragment or a fusion protein can be used. Particularly important fragments are those covering functional domains, such as the domains identified in Figure 2, and domain of sequence homology or divergence amongst the family, such as those that can readily be identified using protein alignment methods and as presented in the Figures.

Antibodies are preferably prepared from regions or discrete fragments of the GPCR proteins. Antibodies can be prepared from any region of the peptide as described herein. However, preferred regions will include those involved in function/activity and/or receptor/binding partner interaction. Figure 2 can be used to identify particularly important regions while sequence alignment can be used to identify conserved and unique sequence fragments.

An antigenic fragment will typically comprise at least 8 contiguous amino acid residues. The antigenic peptide can comprise, however, at least 10, 12, 14, 16 or more amino acid residues. Such fragments can be selected on a physical property, such as fragments correspond to regions that are located on the surface of the protein, e.g., hydrophilic regions or can be selected based on sequence uniqueness (see Figure 2).

Detection on an antibody of the present invention can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase,  $\beta$ -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{35}\text{S}$  or  $^3\text{H}$ .

#### Antibody Uses

The antibodies can be used to isolate one of the proteins of the present invention by standard techniques, such as affinity chromatography or immunoprecipitation. The antibodies can facilitate the purification of the natural protein from cells and recombinantly produced protein expressed in

host cells. In addition, such antibodies are useful to detect the presence of one of the proteins of the present invention in cells or tissues to determine the pattern of expression of the protein among various tissues in an organism and over the course of normal development. Experimental data as provided in Figure 1 indicates that GPCR proteins of the present invention are expressed in humans in the stomach, placenta, kidney, skeletal muscle, liver, bone marrow, and thymus. Specifically, a virtual northern blot shows expression in the stomach. In addition, PCR-based tissue screening panels indicate expression in placenta, kidney, skeletal muscle, liver, bone marrow, and thymus tissue. Further, such antibodies can be used to detect protein *in situ*, *in vitro*, or in a cell lysate or supernatant in order to evaluate the abundance and pattern of expression. Also, such antibodies can be used to assess abnormal tissue distribution or abnormal expression during development or progression of a biological condition. Antibody detection of circulating fragments of the full length protein can be used to identify turnover.

Further, the antibodies can be used to assess expression in disease states such as in active stages of the disease or in an individual with a predisposition toward disease related to the protein's function. When a disorder is caused by an inappropriate tissue distribution, developmental expression, level of expression of the protein, or expressed/processed form, the antibody can be prepared against the normal protein. Experimental data as provided in Figure 1 indicates expression in humans in the stomach, placenta, kidney, skeletal muscle, liver, bone marrow, and thymus. If a disorder is characterized by a specific mutation in the protein, antibodies specific for this mutant protein can be used to assay for the presence of the specific mutant protein.

The antibodies can also be used to assess normal and aberrant subcellular localization of cells in the various tissues in an organism. Experimental data as provided in Figure 1 indicates expression in humans in the stomach, placenta, kidney, skeletal muscle, liver, bone marrow, and thymus. The diagnostic uses can be applied, not only in genetic testing, but also in monitoring a treatment modality. Accordingly, where treatment is ultimately aimed at correcting expression level or the presence of aberrant sequence and aberrant tissue distribution or developmental expression, antibodies directed against the protein or relevant fragments can be used to monitor therapeutic efficacy.

Additionally, antibodies are useful in pharmacogenomic analysis. Thus, antibodies prepared against polymorphic proteins can be used to identify individuals that require modified treatment modalities. The antibodies are also useful as diagnostic tools as an immunological marker for aberrant protein analyzed by electrophoretic mobility, isoelectric point, tryptic peptide digest, and other physical assays known to those in the art.

The antibodies are also useful for tissue typing. Experimental data as provided in Figure 1 indicates expression in humans in the stomach, placenta, kidney, skeletal muscle, liver, bone marrow, and thymus. Thus, where a specific protein has been correlated with expression in a specific tissue, antibodies that are specific for this protein can be used to identify a tissue type.

5 The antibodies are also useful for inhibiting protein function, for example, blocking the binding of the GPCR peptide to a binding partner such as a ligand. These uses can also be applied in a therapeutic context in which treatment involves inhibiting the protein's function. An antibody can be used, for example, to block binding, thus modulating (agonizing or antagonizing) the peptides activity. Antibodies can be prepared against specific fragments containing sites required  
10 for function or against intact protein that is associated with a cell or cell membrane. See Figure 2 for structural information relating to the proteins of the present invention.

The invention also encompasses kits for using antibodies to detect the presence of a protein in a biological sample. The kit can comprise antibodies such as a labeled or labelable antibody and a compound or agent for detecting protein in a biological sample; means for determining the amount  
15 of protein in the sample; means for comparing the amount of protein in the sample with a standard; and instructions for use. Such a kit can be supplied to detect a single protein or epitope or can be configured to detect one of a multitude of epitopes, such as in an antibody detection array. Arrays are described in detail below for nucleic acid arrays and similar methods have been developed for antibody arrays.

### Nucleic Acid Molecules

The present invention further provides isolated nucleic acid molecules that encode a GPCR peptide or protein of the present invention (cDNA, transcript and genomic sequence). Such nucleic acid molecules will consist of, consist essentially of, or comprise a nucleotide sequence that encodes  
25 one of the GPCR peptides of the present invention, an allelic variant thereof, or an ortholog or paralog thereof.

As used herein, an "isolated" nucleic acid molecule is one that is separated from other nucleic acid present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3'  
30 ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. However, there can be some flanking nucleotide sequences, for example up to about 5KB, 4KB, 3KB, 2KB, or 1KB or less, particularly contiguous peptide encoding sequences and peptide

encoding sequences within the same gene but separated by introns in the genomic sequence. The important point is that the nucleic acid is isolated from remote and unimportant flanking sequences such that it can be subjected to the specific manipulations described herein such as recombinant expression, preparation of probes and primers, and other uses specific to the nucleic acid sequences.

5 Moreover, an "isolated" nucleic acid molecule, such as a transcript/cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized. However, the nucleic acid molecule can be fused to other coding or regulatory sequences and still be considered isolated.

10 For example, recombinant DNA molecules contained in a vector are considered isolated. Further examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include *in vivo* or *in vitro* RNA transcripts of the isolated DNA molecules of the present invention. Isolated nucleic acid molecules according to the present invention further include  
15 such molecules produced synthetically.

Accordingly, the present invention provides nucleic acid molecules that consist of the nucleotide sequence shown in Figure 1 or 3 (SEQ ID NO:1, cDNA sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in Figure 2, SEQ ID NO:2. A nucleic acid molecule consists of a nucleotide sequence when the nucleotide  
20 sequence is the complete nucleotide sequence of the nucleic acid molecule.

The present invention further provides nucleic acid molecules that consist essentially of the nucleotide sequence shown in Figure 1 or 3 (SEQ ID NO:1, cDNA sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in Figure 2, SEQ ID NO:2. A nucleic acid molecule consists essentially of a nucleotide sequence when such a  
25 nucleotide sequence is present with only a few additional nucleic acid residues in the final nucleic acid molecule.

The present invention further provides nucleic acid molecules that comprise the nucleotide sequences shown in Figure 1 or 3 (SEQ ID NO:1, cDNA sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in Figure 2, SEQ ID  
30 NO:2. A nucleic acid molecule comprises a nucleotide sequence when the nucleotide sequence is at least part of the final nucleotide sequence of the nucleic acid molecule. In such a fashion, the nucleic acid molecule can be only the nucleotide sequence or have additional nucleic acid residues, such as nucleic acid residues that are naturally associated with it or heterologous nucleotide

sequences. Such a nucleic acid molecule can have a few additional nucleotides or can comprises several hundred or more additional nucleotides. A brief description of how various types of these nucleic acid molecules can be readily made/isolated is provided below.

In Figures 1 and 3, both coding and non-coding sequences are provided. Because of the source of the present invention, human genomic sequences (Figure 3) and cDNA sequences (Figure 1), the nucleic acid molecules in the Figures will contain genomic intronic sequences, 5' and 3' non-coding sequences, gene regulatory regions and non-coding intergenic sequences. In general such sequence features are either noted in Figures 1 and 3 or can readily be identified using computational tools known in the art. As discussed below, some of the non-coding regions, particularly gene regulatory elements such as promoters, are useful for a variety of purposes, e.g. control of heterologous gene expression, target for identifying gene activity modulating compounds, and are particularly claimed as fragments of the genomic sequence provided herein.

The isolated nucleic acid molecules can encode the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature peptide (when the mature form has more than one peptide chain, for instance). Such sequences may play a role in processing of a protein from precursor to a mature form, facilitate protein trafficking, prolong or shorten protein half-life or facilitate manipulation of a protein for assay or production, among other things. As generally is the case *in situ*, the additional amino acids may be processed away from the mature protein by cellular enzymes.

As mentioned above, the isolated nucleic acid molecules include, but are not limited to, the sequence encoding the GPCR peptide alone, the sequence encoding the mature peptide and additional coding sequences, such as a leader or secretory sequence (e.g., a pre-pro or pro-protein sequence), the sequence encoding the mature peptide, with or without the additional coding sequences, plus additional non-coding sequences, for example introns and non-coding 5' and 3' sequences such as transcribed but non-translated sequences that play a role in transcription, mRNA processing (including splicing and polyadenylation signals), ribosome binding and stability of mRNA. In addition, the nucleic acid molecule may be fused to a marker sequence encoding, for example, a peptide that facilitates purification.

Isolated nucleic acid molecules can be in the form of RNA, such as mRNA, or in the form DNA, including cDNA and genomic DNA obtained by cloning or produced by chemical synthetic techniques or by a combination thereof. The nucleic acid, especially DNA, can be double-stranded or single-stranded. Single-stranded nucleic acid can be the coding strand (sense strand) or the non-

coding strand (anti-sense strand).

The invention further provides nucleic acid molecules that encode fragments of the peptides of the present invention as well as nucleic acid molecules that encode obvious variants of the GPCR proteins of the present invention that are described above. Such nucleic acid molecules may be naturally occurring, such as allelic variants (same locus), paralogs (different locus), and orthologs (different organism), or may be constructed by recombinant DNA methods or by chemical synthesis. Such non-naturally occurring variants may be made by mutagenesis techniques, including those applied to nucleic acid molecules, cells, or organisms. Accordingly, as discussed above, the variants can contain nucleotide substitutions, deletions, inversions and insertions.

Variation can occur in either or both the coding and non-coding regions. The variations can produce both conservative and non-conservative amino acid substitutions.

The present invention further provides non-coding fragments of the nucleic acid molecules provided in Figures 1 and 3. Preferred non-coding fragments include, but are not limited to, promoter sequences, enhancer sequences, gene modulating sequences and gene termination sequences. Such fragments are useful in controlling heterologous gene expression and in developing screens to identify gene-modulating agents. A promoter can readily be identified as being 5' to the ATG start site in the genomic sequence provided in Figure 3.

A fragment comprises a contiguous nucleotide sequence greater than 12 or more nucleotides. Further, a fragment could be at least 30, 40, 50, 100, 250 or 500 nucleotides in length.

The length of the fragment will be based on its intended use. For example, the fragment can encode epitope bearing regions of the peptide, or can be useful as DNA probes and primers. Such fragments can be isolated using the known nucleotide sequence to synthesize an oligonucleotide probe. A labeled probe can then be used to screen a cDNA library, genomic DNA library, or mRNA to isolate nucleic acid corresponding to the coding region. Further, primers can be used in PCR reactions to clone specific regions of gene.

A probe/primer typically comprises substantially a purified oligonucleotide or oligonucleotide pair. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 20, 25, 40, 50 or more consecutive nucleotides.

Orthologs, homologs, and allelic variants can be identified using methods well known in the art. As described in the Peptide Section, these variants comprise a nucleotide sequence encoding a peptide that is typically 60-70%, 70-80%, 80-90%, and more typically at least about 90-95% or more homologous to the nucleotide sequence shown in the Figure sheets or a fragment of this

sequence. Such nucleic acid molecules can readily be identified as being able to hybridize under moderate to stringent conditions, to the nucleotide sequence shown in the Figure sheets or a fragment of the sequence. Allelic variants can readily be determined by genetic locus of the encoding gene. As indicated by the data presented in Figure 3, the map position was determined to be on chromosome 6 by radiation hybrid mapping.

Figure 3 provides information on a SNP variant, G1711T, which has been found in a gene encoding the GPCR protein of the present invention. The change in the amino acid sequence caused by this SNP is indicated in Figure 3 and can readily be determined using the universal genetic code and the protein sequence provided in Figure 2 as a reference.

As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences encoding a peptide at least 60-70% homologous to each other typically remain hybridized to each other. The conditions can be such that sequences at least about 60%, at least about 70%, or at least about 80% or more homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. One example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65C. Examples of moderate to low stringency hybridization conditions are well known in the art.

#### Nucleic Acid Molecule Uses

The nucleic acid molecules of the present invention are useful for probes, primers, chemical intermediates, and in biological assays. The nucleic acid molecules are useful as a hybridization probe for messenger RNA, transcript/cDNA and genomic DNA to isolate full-length cDNA and genomic clones encoding the peptide described in Figure 2 and to isolate cDNA and genomic clones that correspond to variants (alleles, orthologs, etc.) producing the same or related peptides shown in Figure 2. As illustrated in Figure 3, G1711T is a known SNP variant.

The probe can correspond to any sequence along the entire length of the nucleic acid molecules provided in the Figures. Accordingly, it could be derived from 5' noncoding regions, the coding region, and 3' noncoding regions. However, as discussed, fragments are not to be construed as encompassing fragments disclosed prior to the present invention.

The nucleic acid molecules are also useful as primers for PCR to amplify any given region

of a nucleic acid molecule and are useful to synthesize antisense molecules of desired length and sequence.

The nucleic acid molecules are also useful for constructing recombinant vectors. Such vectors include expression vectors that express a portion of, or all of, the peptide sequences.

5 Vectors also include insertion vectors, used to integrate into another nucleic acid molecule sequence, such as into the cellular genome, to alter *in situ* expression of a gene and/or gene product. For example, an endogenous coding sequence can be replaced via homologous recombination with all or part of the coding region containing one or more specifically introduced mutations.

The nucleic acid molecules are also useful for expressing antigenic portions of the proteins.

10 The nucleic acid molecules are also useful as probes for determining the chromosomal positions of the nucleic acid molecules by means of *in situ* hybridization methods. As indicated by the data presented in Figure 3, the map position was determined to be on chromosome 6 by radiation hybrid mapping.

The nucleic acid molecules are also useful in making vectors containing the gene regulatory  
15 regions of the nucleic acid molecules of the present invention.

The nucleic acid molecules are also useful for designing ribozymes corresponding to all, or a part, of the mRNA produced from the nucleic acid molecules described herein.

The nucleic acid molecules are also useful for making vectors that express part, or all, of the peptides.

20 The nucleic acid molecules are also useful for constructing host cells expressing a part, or all, of the nucleic acid molecules and peptides.

The nucleic acid molecules are also useful for constructing transgenic animals expressing all, or a part, of the nucleic acid molecules and peptides.

25 The nucleic acid molecules are also useful as hybridization probes for determining the presence, level, form and distribution of nucleic acid expression. Experimental data as provided in Figure 1 indicates that GPCR proteins of the present invention are expressed in humans in the stomach, placenta, kidney, skeletal muscle, liver, bone marrow, and thymus. Specifically, a virtual northern blot shows expression in the stomach. In addition, PCR-based tissue screening panels indicate expression in placenta, kidney, skeletal muscle, liver, bone marrow, and thymus tissue.

30 Accordingly, the probes can be used to detect the presence of, or to determine levels of, a specific nucleic acid molecule in cells, tissues, and in organisms. The nucleic acid whose level is determined can be DNA or RNA. Accordingly, probes corresponding to the peptides described herein can be used to assess expression and/or gene copy number in a given cell, tissue, or

organism. These uses are relevant for diagnosis of disorders involving an increase or decrease in GPCR protein expression relative to normal results.

*In vitro* techniques for detection of mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detecting DNA include Southern hybridizations and *in situ* hybridization.

Probes can be used as a part of a diagnostic test kit for identifying cells or tissues that express a GPCR protein, such as by measuring a level of a receptor-encoding nucleic acid in a sample of cells from a subject e.g., mRNA or genomic DNA, or determining if a receptor gene has been mutated. Experimental data as provided in Figure 1 indicates that GPCR proteins of the present invention are expressed in humans in the stomach, placenta, kidney, skeletal muscle, liver, bone marrow, and thymus. Specifically, a virtual northern blot shows expression in the stomach. In addition, PCR-based tissue screening panels indicate expression in placenta, kidney, skeletal muscle, liver, bone marrow, and thymus tissue.

Nucleic acid expression assays are useful for drug screening to identify compounds that modulate GPCR nucleic acid expression.

The invention thus provides a method for identifying a compound that can be used to treat a disorder associated with nucleic acid expression of the GPCR gene, particularly biological and pathological processes that are mediated by the GPCR in cells and tissues that express it. Experimental data as provided in Figure 1 indicates expression in humans in the stomach, placenta, kidney, skeletal muscle, liver, bone marrow, and thymus. The method typically includes assaying the ability of the compound to modulate the expression of the GPCR nucleic acid and thus identifying a compound that can be used to treat a disorder characterized by undesired GPCR nucleic acid expression. The assays can be performed in cell-based and cell-free systems. Cell-based assays include cells naturally expressing the GPCR nucleic acid or recombinant cells genetically engineered to express specific nucleic acid sequences.

The assay for GPCR nucleic acid expression can involve direct assay of nucleic acid levels, such as mRNA levels, or on collateral compounds involved in the signal pathway. Further, the expression of genes that are up- or down-regulated in response to the GPCR protein signal pathway can also be assayed. In this embodiment the regulatory regions of these genes can be operably linked to a reporter gene such as luciferase.

Thus, modulators of GPCR gene expression can be identified in a method wherein a cell is contacted with a candidate compound and the expression of mRNA determined. The level of expression of GPCR mRNA in the presence of the candidate compound is compared to the level of

expression of GPCR mRNA in the absence of the candidate compound. The candidate compound can then be identified as a modulator of nucleic acid expression based on this comparison and be used, for example to treat a disorder characterized by aberrant nucleic acid expression. When expression of mRNA is statistically significantly greater in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of nucleic acid expression. When nucleic acid expression is statistically significantly less in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of nucleic acid expression.

The invention further provides methods of treatment, with the nucleic acid as a target, using a compound identified through drug screening as a gene modulator to modulate GPCR nucleic acid expression, particularly to modulate activities within a cell or tissue that expresses the proteins. Experimental data as provided in Figure 1 indicates that GPCR proteins of the present invention are expressed in humans in the stomach, placenta, kidney, skeletal muscle, liver, bone marrow, and thymus. Specifically, a virtual northern blot shows expression in the stomach. In addition, PCR-based tissue screening panels indicate expression in placenta, kidney, skeletal muscle, liver, bone marrow, and thymus tissue. Modulation includes both up-regulation (i.e. activation or agonization) or down-regulation (suppression or antagonization) of nucleic acid expression.

Alternatively, a modulator for GPCR nucleic acid expression can be a small molecule or drug identified using the screening assays described herein as long as the drug or small molecule inhibits the GPCR nucleic acid expression in the cells and tissues that express the protein. Experimental data as provided in Figure 1 indicates expression in humans in the stomach, placenta, kidney, skeletal muscle, liver, bone marrow, and thymus.

The nucleic acid molecules are also useful for monitoring the effectiveness of modulating compounds on the expression or activity of the GPCR gene in clinical trials or in a treatment regimen. Thus, the gene expression pattern can serve as a barometer for the continuing effectiveness of treatment with the compound, particularly with compounds to which a patient can develop resistance. The gene expression pattern can also serve as a marker indicative of a physiological response of the affected cells to the compound. Accordingly, such monitoring would allow either increased administration of the compound or the administration of alternative compounds to which the patient has not become resistant. Similarly, if the level of nucleic acid expression falls below a desirable level, administration of the compound could be commensurately decreased.

The nucleic acid molecules are also useful in diagnostic assays for qualitative changes in

GPCR nucleic acid, and particularly in qualitative changes that lead to pathology. The nucleic acid molecules can be used to detect mutations in GPCR genes and gene expression products such as mRNA. The nucleic acid molecules can be used as hybridization probes to detect naturally-occurring genetic mutations in the GPCR gene and thereby to determine whether a subject with the mutation is at risk for a disorder caused by the mutation. Mutations include deletion, addition, or substitution of one or more nucleotides in the gene, chromosomal rearrangement, such as inversion or transposition, modification of genomic DNA, such as aberrant methylation patterns or changes in gene copy number, such as amplification. Detection of a mutated form of the GPCR gene associated with a dysfunction provides a diagnostic tool for an active disease or susceptibility to disease when the disease results from overexpression, underexpression, or altered expression of a GPCR protein.

Individuals carrying mutations in the GPCR gene can be detected at the nucleic acid level by a variety of techniques. Figure 3 provides information on a SNP variant, G1711T, which has been found in a gene encoding the GPCR protein of the present invention. The change in the amino acid sequence caused by this SNP is indicated in Figure 3 and can readily be determined using the universal genetic code and the protein sequence provided in Figure 2 as a reference. As indicated by the data presented in Figure 3, the map position was determined to be on chromosome 6 by radiation hybrid mapping. Genomic DNA can be analyzed directly or can be amplified by using PCR prior to analysis. RNA or cDNA can be used in the same way. In some uses, detection of the mutation involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g. U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran *et al.*, *Science* 241:1077-1080 (1988); and Nakazawa *et al.*, *PNAS* 91:360-364 (1994)), the latter of which can be particularly useful for detecting point mutations in the gene (see Abravaya *et al.*, *Nucleic Acids Res.* 23:675-682 (1995)). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to a gene under conditions such that hybridization and amplification of the gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. Deletions and insertions can be detected by a change in size of the amplified product compared to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to normal RNA or antisense DNA sequences.

Alternatively, mutations in a GPCR gene can be directly identified, for example, by

alterations in restriction enzyme digestion patterns determined by gel electrophoresis.

Further, sequence-specific ribozymes (U.S. Patent No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site. Perfectly matched sequences can be distinguished from mismatched sequences by nuclease cleavage

5 digestion assays or by differences in melting temperature.

Sequence changes at specific locations can also be assessed by nuclease protection assays such as RNase and S1 protection or the chemical cleavage method. Furthermore, sequence differences between a mutant GPCR gene and a wild-type gene can be determined by direct DNA sequencing. A variety of automated sequencing procedures can be utilized when performing the diagnostic assays (Naeve, C.W., (1995) *Biotechniques* 19:448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen *et al.*, *Adv. Chromatogr.* 36:127-162 (1996); and Griffin *et al.*, *Appl. Biochem. Biotechnol.* 38:147-159 (1993)).

Other methods for detecting mutations in the gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA duplexes (Myers *et al.*, *Science* 230:1242 (1985)); Cotton *et al.*, *PNAS* 85:4397 (1988); Saleeba *et al.*, *Meth. Enzymol.* 217:286-295 (1992)), electrophoretic mobility of mutant and wild type nucleic acid is compared (Orita *et al.*, *PNAS* 86:2766 (1989); Cotton *et al.*, *Mutat. Res.* 285:125-144 (1993); and Hayashi *et al.*, *Genet. Anal. Tech. Appl.* 9:73-79 (1992)), and movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (Myers *et al.*, *Nature* 313:495 (1985)). Examples of other techniques for detecting point mutations include selective oligonucleotide hybridization, selective amplification, and selective primer extension.

The nucleic acid molecules are also useful for testing an individual for a genotype that while not necessarily causing the disease, nevertheless affects the treatment modality. Thus, the nucleic acid molecules can be used to study the relationship between an individual's genotype and the individual's response to a compound used for treatment (pharmacogenomic relationship).

Accordingly, the nucleic acid molecules described herein can be used to assess the mutation content of the GPCR gene in an individual in order to select an appropriate compound or dosage regimen for treatment. As illustrated in Figure 3, G1711T is a known SNP variant.

Thus nucleic acid molecules displaying genetic variations that affect treatment provide a diagnostic target that can be used to tailor treatment in an individual. Accordingly, the production of recombinant cells and animals containing these polymorphisms allow effective clinical design of treatment compounds and dosage regimens.

The nucleic acid molecules are thus useful as antisense constructs to control GPCR gene expression in cells, tissues, and organisms. A DNA antisense nucleic acid molecule is designed to be complementary to a region of the gene involved in transcription, preventing transcription and hence production of GPCR protein. An antisense RNA or DNA nucleic acid molecule would  
5 hybridize to the mRNA and thus block translation of mRNA into GPCR protein.

Alternatively, a class of antisense molecules can be used to inactivate mRNA in order to decrease expression of GPCR nucleic acid. Accordingly, these molecules can treat a disorder characterized by abnormal or undesired GPCR nucleic acid expression. This technique involves cleavage by means of ribozymes containing nucleotide sequences complementary to one or more  
10 regions in the mRNA that attenuate the ability of the mRNA to be translated. Possible regions include coding regions and particularly coding regions corresponding to the catalytic and other functional activities of the GPCR protein, such as ligand binding.

The nucleic acid molecules also provide vectors for gene therapy in patients containing cells that are aberrant in GPCR gene expression. Thus, recombinant cells, which include the patient's  
15 cells that have been engineered *ex vivo* and returned to the patient, are introduced into an individual where the cells produce the desired GPCR protein to treat the individual.

The invention also encompasses kits for detecting the presence of a GPCR nucleic acid in a biological sample. Experimental data as provided in Figure 1 indicates that GPCR proteins of the present invention are expressed in humans in the stomach, placenta, kidney, skeletal muscle, liver,  
20 bone marrow, and thymus. Specifically, a virtual northern blot shows expression in the stomach. In addition, PCR-based tissue screening panels indicate expression in placenta, kidney, skeletal muscle, liver, bone marrow, and thymus tissue. For example, the kit can comprise reagents such as a labeled or labelable nucleic acid or agent capable of detecting GPCR nucleic acid in a biological sample; means for determining the amount of GPCR nucleic acid in the sample; and means for  
25 comparing the amount of GPCR nucleic acid in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect GPCR protein mRNA or DNA.

#### Nucleic Acid Arrays

30 The present invention further provides nucleic acid detection kits, such as arrays or microarrays of nucleic acid molecules that are based on the sequence information provided in Figures 1 and 3 (SEQ ID NOS:1 and 3).

As used herein "Arrays" or "Microarrays" refers to an array of distinct polynucleotides or oligonucleotides synthesized on a substrate, such as paper, nylon or other type of membrane, filter, chip, glass slide, or any other suitable solid support. In one embodiment, the microarray is prepared and used according to the methods described in US Patent 5,837,832, Chee et al., PCT application W095/11995 (Chee et al.), Lockhart, D. J. et al. (1996; Nat. Biotech. 14: 1675-1680) and Schena, M. et al. (1996; Proc. Natl. Acad. Sci. 93: 10614-10619), all of which are incorporated herein in their entirety by reference. In other embodiments, such arrays are produced by the methods described by Brown et. al., US Patent No. 5,807,522.

The microarray or detection kit is preferably composed of a large number of unique, single-stranded nucleic acid sequences, usually either synthetic antisense oligonucleotides or fragments of cDNAs, fixed to a solid support. The oligonucleotides are preferably about 6-60 nucleotides in length, more preferably 15-30 nucleotides in length, and most preferably about 20-25 nucleotides in length. For a certain type of microarray or detection kit, it may be preferable to use oligonucleotides that are only 7-20 nucleotides in length. The microarray or detection kit may contain oligonucleotides that cover the known 5', or 3', sequence, sequential oligonucleotides which cover the full length sequence; or unique oligonucleotides selected from particular areas along the length of the sequence. Polynucleotides used in the microarray or detection kit may be oligonucleotides that are specific to a gene or genes of interest.

In order to produce oligonucleotides to a known sequence for a microarray or detection kit, the gene(s) of interest (or an ORF identified from the contigs of the present invention) is typically examined using a computer algorithm which starts at the 5' or at the 3' end of the nucleotide sequence. Typical algorithms will then identify oligomers of defined length that are unique to the gene, have a GC content within a range suitable for hybridization, and lack predicted secondary structure that may interfere with hybridization. In certain situations it may be appropriate to use pairs of oligonucleotides on a microarray or detection kit. The "pairs" will be identical, except for one nucleotide that preferably is located in the center of the sequence. The second oligonucleotide in the pair (mismatched by one) serves as a control. The number of oligonucleotide pairs may range from two to one million. The oligomers are synthesized at designated areas on a substrate using a light-directed chemical process. The substrate may be paper, nylon or other type of membrane, filter, chip, glass slide or any other suitable solid support.

In another aspect, an oligonucleotide may be synthesized on the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT

application W095/251116 (Baldeschweiler et al.) which is incorporated herein in its entirety by reference. In another aspect, a "gridded" array analogous to a dot (or slot) blot may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array, such as those described above, may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536, 6144 or more oligonucleotides, or any other number between two and one million which lends itself to the efficient use of commercially available instrumentation.

In order to conduct sample analysis using a microarray or detection kit, the RNA or DNA from a biological sample is made into hybridization probes. The mRNA is isolated, and cDNA is produced and used as a template to make antisense RNA (aRNA). The aRNA is amplified in the presence of fluorescent nucleotides, and labeled probes are incubated with the microarray or detection kit so that the probe sequences hybridize to complementary oligonucleotides of the microarray or detection kit. Incubation conditions are adjusted so that hybridization occurs with precise complementary matches or with various degrees of less complementarity. After removal of nonhybridized probes, a scanner is used to determine the levels and patterns of fluorescence. The scanned images are examined to determine degree of complementarity and the relative abundance of each oligonucleotide sequence on the microarray or detection kit. The biological samples may be obtained from any bodily fluids (such as blood, urine, saliva, phlegm, gastric juices, etc.), cultured cells, biopsies, or other tissue preparations. A detection system may be used to measure the absence, presence, and amount of hybridization for all of the distinct sequences simultaneously. This data may be used for large scale correlation studies on the sequences, expression patterns, mutations, variants, or polymorphisms among samples.

Using such arrays, the present invention provides methods to identify the expression of the GPCR proteins/peptides of the present invention. In detail, such methods comprise incubating a test sample with one or more nucleic acid molecules and assaying for binding of the nucleic acid molecule with components within the test sample. Such assays will typically involve arrays comprising many genes, at least one of which is a gene of the present invention and or alleles of the GPCR gene of the present invention. Figure 3 provides information on a SNP variant, G1711T, which has been found in a gene encoding the GPCR protein of the present invention. The change in the amino acid sequence caused by this SNP is indicated in Figure 3 and can readily be determined using the universal genetic code and the protein sequence

provided in Figure 2 as a reference.

Conditions for incubating a nucleic acid molecule with a test sample vary. Incubation conditions depend on the format employed in the assay, the detection methods employed, and the type and nature of the nucleic acid molecule used in the assay. One skilled in the art will

5 recognize that any one of the commonly available hybridization, amplification or array assay formats can readily be adapted to employ the novel fragments of the Human genome disclosed herein. Examples of such assays can be found in Chard, T, *An Introduction to Radioimmunoassay and Related Techniques*, Elsevier Science Publishers, Amsterdam, The Netherlands (1986); Bullock, G. R. *et al.*, *Techniques in Immunocytochemistry*, Academic Press, Orlando, FL Vol. 1 (1982), Vol. 2 (1983), Vol. 3 (1985); Tijssen, P., *Practice and Theory of Enzyme Immunoassays: Laboratory Techniques in Biochemistry and Molecular Biology*, Elsevier Science Publishers, Amsterdam, The Netherlands (1985).

The test samples of the present invention include cells, protein or membrane extracts of cells. The test sample used in the above-described method will vary based on the assay format, nature of the detection method and the tissues, cells or extracts used as the sample to be assayed. Methods for preparing nucleic acid extracts or of cells are well known in the art and can be readily be adapted in order to obtain a sample that is compatible with the system utilized.

In another embodiment of the present invention, kits are provided which contain the necessary reagents to carry out the assays of the present invention.

20 Specifically, the invention provides a compartmentalized kit to receive, in close confinement, one or more containers which comprises: (a) a first container comprising one of the nucleic acid molecules that can bind to a fragment of the Human genome disclosed herein; and (b) one or more other containers comprising one or more of the following: wash reagents, reagents capable of detecting presence of a bound nucleic acid.

25 In detail, a compartmentalized kit includes any kit in which reagents are contained in separate containers. Such containers include small glass containers, plastic containers, strips of plastic, glass or paper, or arraying material such as silica. Such containers allows one to efficiently transfer reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated, and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a container which will accept the test sample, a container which contains the nucleic acid probe, containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, etc.), and containers which contain the reagents used to detect the bound probe. One skilled in

the art will readily recognize that the previously unidentified GPCR genes of the present invention can be routinely identified using the sequence information disclosed herein can be readily incorporated into one of the established kit formats which are well known in the art, particularly expression arrays.

5

#### Vectors/host cells

The invention also provides vectors containing the nucleic acid molecules described herein. The term "vector" refers to a vehicle, preferably a nucleic acid molecule, which can transport the nucleic acid molecules. When the vector is a nucleic acid molecule, the nucleic acid molecules are covalently linked to the vector nucleic acid. With this aspect of the invention, the vector includes a plasmid, single or double stranded phage, a single or double stranded RNA or DNA viral vector, or artificial chromosome, such as a BAC, PAC, YAC, OR MAC.

10

A vector can be maintained in the host cell as an extrachromosomal element where it replicates and produces additional copies of the nucleic acid molecules. Alternatively, the vector may integrate into the host cell genome and produce additional copies of the nucleic acid molecules when the host cell replicates.

15

The invention provides vectors for the maintenance (cloning vectors) or vectors for expression (expression vectors) of the nucleic acid molecules. The vectors can function in procaryotic or eukaryotic cells or in both (shuttle vectors).

20

Expression vectors contain cis-acting regulatory regions that are operably linked in the vector to the nucleic acid molecules such that transcription of the nucleic acid molecules is allowed in a host cell. The nucleic acid molecules can be introduced into the host cell with a separate nucleic acid molecule capable of affecting transcription. Thus, the second nucleic acid molecule may provide a trans-acting factor interacting with the cis-regulatory control region to allow transcription of the nucleic acid molecules from the vector. Alternatively, a trans-acting factor may be supplied by the host cell. Finally, a trans-acting factor can be produced from the vector itself. It is understood, however, that in some embodiments, transcription and/or translation of the nucleic acid molecules can occur in a cell-free system.

25

The regulatory sequence to which the nucleic acid molecules described herein can be operably linked include promoters for directing mRNA transcription. These include, but are not limited to, the left promoter from bacteriophage  $\lambda$ , the lac, TRP, and TAC promoters from *E. coli*, the early and late promoters from SV40, the CMV immediate early promoter, the adenovirus early

30

and late promoters, and retrovirus long-terminal repeats.

In addition to control regions that promote transcription, expression vectors may also include regions that modulate transcription, such as repressor binding sites and enhancers. Examples include the SV40 enhancer, the cytomegalovirus immediate early enhancer, polyoma  
5 enhancer, adenovirus enhancers, and retrovirus LTR enhancers.

In addition to containing sites for transcription initiation and control, expression vectors can also contain sequences necessary for transcription termination and, in the transcribed region a ribosome binding site for translation. Other regulatory control elements for expression include initiation and termination codons as well as polyadenylation signals. The person of ordinary skill in  
10 the art would be aware of the numerous regulatory sequences that are useful in expression vectors. Such regulatory sequences are described, for example, in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989).

A variety of expression vectors can be used to express a nucleic acid molecule. Such  
15 vectors include chromosomal, episomal, and virus-derived vectors, for example vectors derived from bacterial plasmids, from bacteriophage, from yeast episomes, from yeast chromosomal elements, including yeast artificial chromosomes, from viruses such as baculoviruses, papovaviruses such as SV40, Vaccinia viruses, adenoviruses, poxviruses, pseudorabies viruses, and retroviruses. Vectors may also be derived from combinations of these sources such as those derived  
20 from plasmid and bacteriophage genetic elements, eg. cosmids and phagemids. Appropriate cloning and expression vectors for prokaryotic and eukaryotic hosts are described in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989).

The regulatory sequence may provide constitutive expression in one or more host cells (i.e.  
25 tissue specific) or may provide for inducible expression in one or more cell types such as by temperature, nutrient additive, or exogenous factor such as a hormone or other ligand. A variety of vectors providing for constitutive and inducible expression in prokaryotic and eukaryotic hosts are well known to those of ordinary skill in the art.

The nucleic acid molecules can be inserted into the vector nucleic acid by well-known  
30 methodology. Generally, the DNA sequence that will ultimately be expressed is joined to an expression vector by cleaving the DNA sequence and the expression vector with one or more restriction enzymes and then ligating the fragments together. Procedures for restriction enzyme digestion and ligation are well known to those of ordinary skill in the art.

The vector containing the appropriate nucleic acid molecule can be introduced into an appropriate host cell for propagation or expression using well-known techniques. Bacterial cells include, but are not limited to, *E. coli*, *Streptomyces*, and *Salmonella typhimurium*. Eukaryotic cells include, but are not limited to, yeast, insect cells such as *Drosophila*, animal cells such as COS and CHO cells, and plant cells.

As described herein, it may be desirable to express the peptide as a fusion protein. Accordingly, the invention provides fusion vectors that allow for the production of the peptides. Fusion vectors can increase the expression of a recombinant protein, increase the solubility of the recombinant protein, and aid in the purification of the protein by acting for example as a ligand for affinity purification. A proteolytic cleavage site may be introduced at the junction of the fusion moiety so that the desired peptide can ultimately be separated from the fusion moiety. Proteolytic enzymes include, but are not limited to, factor Xa, thrombin, and enterokinase. Typical fusion expression vectors include pGEX (Smith *et al.*, *Gene* 67:31-40 (1988)), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. Examples of suitable inducible non-fusion *E. coli* expression vectors include pTtr (Amann *et al.*, *Gene* 69:301-315 (1988)) and pET 11d (Studier *et al.*, *Gene Expression Technology: Methods in Enzymology* 185:60-89 (1990)).

Recombinant protein expression can be maximized in a host bacteria by providing a genetic background wherein the host cell has an impaired capacity to proteolytically cleave the recombinant protein. (Gottesman, S., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 119-128). Alternatively, the sequence of the nucleic acid molecule of interest can be altered to provide preferential codon usage for a specific host cell, for example *E. coli*. (Wada *et al.*, *Nucleic Acids Res.* 20:2111-2118 (1992)).

The nucleic acid molecules can also be expressed by expression vectors that are operative in yeast. Examples of vectors for expression in yeast e.g., *S. cerevisiae* include pYepSec1 (Baldari, *et al.*, *EMBO J.* 6:229-234 (1987)), pMFa (Kurjan *et al.*, *Cell* 30:933-943(1982)), pJRY88 (Schultz *et al.*, *Gene* 54:113-123 (1987)), and pYES2 (Invitrogen Corporation, San Diego, CA).

The nucleic acid molecules can also be expressed in insect cells using, for example, baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf9 cells) include the pAc series (Smith *et al.*, *Mol. Cell Biol.* 3:2156-2165 (1983)) and the pVL series (Lucklow *et al.*, *Virology* 170:31-39 (1989)).

In certain embodiments of the invention, the nucleic acid molecules described herein are

expressed in mammalian cells using mammalian expression vectors. Examples of mammalian expression vectors include pCDM8 (Seed, B. *Nature* 329:840(1987)) and pMT2PC (Kaufman *et al.*, *EMBO J.* 6:187-195 (1987)).

The expression vectors listed herein are provided by way of example only of the well-known vectors available to those of ordinary skill in the art that would be useful to express the nucleic acid molecules. The person of ordinary skill in the art would be aware of other vectors suitable for maintenance propagation or expression of the nucleic acid molecules described herein. These are found for example in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.

The invention also encompasses vectors in which the nucleic acid sequences described herein are cloned into the vector in reverse orientation, but operably linked to a regulatory sequence that permits transcription of antisense RNA. Thus, an antisense transcript can be produced to all, or to a portion, of the nucleic acid molecule sequences described herein, including both coding and non-coding regions. Expression of this antisense RNA is subject to each of the parameters described above in relation to expression of the sense RNA (regulatory sequences, constitutive or inducible expression, tissue-specific expression).

The invention also relates to recombinant host cells containing the vectors described herein. Host cells therefore include prokaryotic cells, lower eukaryotic cells such as yeast, other eukaryotic cells such as insect cells, and higher eukaryotic cells such as mammalian cells.

The recombinant host cells are prepared by introducing the vector constructs described herein into the cells by techniques readily available to the person of ordinary skill in the art. These include, but are not limited to, calcium phosphate transfection, DEAE-dextran-mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, lipofection, and other techniques such as those found in Sambrook, *et al.* (*Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

Host cells can contain more than one vector. Thus, different nucleotide sequences can be introduced on different vectors of the same cell. Similarly, the nucleic acid molecules can be introduced either alone or with other nucleic acid molecules that are not related to the nucleic acid molecules such as those providing trans-acting factors for expression vectors. When more than one vector is introduced into a cell, the vectors can be introduced independently, co-introduced or joined to the nucleic acid molecule vector.

In the case of bacteriophage and viral vectors, these can be introduced into cells as packaged or encapsulated virus by standard procedures for infection and transduction. Viral vectors can be replication-competent or replication-defective. In the case in which viral replication is defective, replication will occur in host cells providing functions that complement the defects.

5 Vectors generally include selectable markers that enable the selection of the subpopulation of cells that contain the recombinant vector constructs. The marker can be contained in the same vector that contains the nucleic acid molecules described herein or may be on a separate vector. Markers include tetracycline or ampicillin-resistance genes for prokaryotic host cells and dihydrofolate reductase or neomycin resistance for eukaryotic host cells. However, any marker that  
10 provides selection for a phenotypic trait will be effective.

While the mature proteins can be produced in bacteria, yeast, mammalian cells, and other cells under the control of the appropriate regulatory sequences, cell-free transcription and translation systems can also be used to produce these proteins using RNA derived from the DNA constructs described herein.

15 Where secretion of the peptide is desired, which is difficult to achieve with multi-transmembrane domain containing proteins such as GPCRs, appropriate secretion signals are incorporated into the vector. The signal sequence can be endogenous to the peptides or heterologous to these peptides.

Where the peptide is not secreted into the medium, which is typically the case with GPCRs,  
20 the protein can be isolated from the host cell by standard disruption procedures, including freeze thaw, sonication, mechanical disruption, use of lysing agents and the like. The peptide can then be recovered and purified by well-known purification methods including ammonium sulfate precipitation, acid extraction, anion or cationic exchange chromatography, phosphocellulose chromatography, hydrophobic-interaction chromatography, affinity chromatography,  
25 hydroxylapatite chromatography, lectin chromatography, or high performance liquid chromatography.

It is also understood that depending upon the host cell in recombinant production of the peptides described herein, the peptides can have various glycosylation patterns, depending upon the cell, or maybe non-glycosylated as when produced in bacteria. In addition, the peptides may  
30 include an initial modified methionine in some cases as a result of a host-mediated process.

#### Uses of vectors and host cells

The recombinant host cells expressing the peptides described herein have a variety of uses. First, the cells are useful for producing a GPCR protein or peptide that can be further purified to produce desired amounts of GPCR protein or fragments. Thus, host cells containing expression vectors are useful for peptide production.

5 Host cells are also useful for conducting cell-based assays involving the GPCR protein or GPCR protein fragments, such as those described above as well as other formats known in the art. Thus, a recombinant host cell expressing a native GPCR protein is useful for assaying compounds that stimulate or inhibit GPCR protein function.

10 Host cells are also useful for identifying GPCR protein mutants in which these functions are affected. If the mutants naturally occur and give rise to a pathology, host cells containing the mutations are useful to assay compounds that have a desired effect on the mutant GPCR protein (for example, stimulating or inhibiting function) which may not be indicated by their effect on the native GPCR protein.

15 Genetically engineered host cells can be further used to produce non-human transgenic animals. A transgenic animal is preferably a mammal, for example a rodent, such as a rat or mouse, in which one or more of the cells of the animal include a transgene. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal in one or more cell types or tissues of the transgenic animal. These animals are useful for studying the function of a GPCR protein and identifying and  
20 evaluating modulators of GPCR protein activity. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, and amphibians.

A transgenic animal can be produced by introducing nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. Any of the GPCR protein nucleotide sequences can be  
25 introduced as a transgene into the genome of a non-human animal, such as a mouse.

Any of the regulatory or other sequences useful in expression vectors can form part of the transgenic sequence. This includes intronic sequences and polyadenylation signals, if not already included. A tissue-specific regulatory sequence(s) can be operably linked to the transgene to direct expression of the GPCR protein to particular cells.

30 Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009, both by Leder *et al.*, U.S. Patent No. 4,873,191 by Wagner *et al.* and in Hogan, B., *Manipulating the Mouse Embryo*, (Cold Spring

Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the transgene in its genome and/or expression of transgenic mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene can further be bred to other transgenic animals carrying other transgenes. A transgenic animal also includes animals in which the entire animal or tissues in the animal have been produced using the homologously recombinant host cells described herein.

In another embodiment, transgenic non-human animals can be produced which contain selected systems that allow for regulated expression of the transgene. One example of such a system is the *cre/loxP* recombinase system of bacteriophage P1. For a description of the *cre/loxP* recombinase system, see, e.g., Lakso *et al.* *PNAS* 89:6232-6236 (1992). Another example of a recombinase system is the FLP recombinase system of *S. cerevisiae* (O'Gorman *et al.* *Science* 251:1351-1355 (1991)). If a *cre/loxP* recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the *Cre* recombinase and a selected protein is required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, I. *et al.* *Nature* 385:810-813 (1997) and PCT International Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell, e.g., a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter G<sub>0</sub> phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyst and then transferred to pseudopregnant female foster animal. The offspring born of this female foster animal will be a clone of the animal from which the cell, e.g., the somatic cell, is isolated.

Transgenic animals containing recombinant cells that express the peptides described herein are useful to conduct the assays described herein in an *in vivo* context. Accordingly, the various physiological factors that are present *in vivo* and that could effect ligand binding, GPCR protein activation, and signal transduction, may not be evident from *in vitro* cell-free or cell-based assays. Accordingly, it is useful to provide non-human transgenic animals to assay *in vivo* GPCR protein function, including ligand interaction, the effect of specific mutant GPCR proteins on GPCR protein

function and ligand interaction, and the effect of chimeric GPCR proteins. It is also possible to assess the effect of null mutations, that is mutations that substantially or completely eliminate one or more GPCR protein functions.

5 All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the above-  
10 described modes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.

### Claims

That which is claimed is:

1. An isolated peptide consisting of an amino acid sequence selected from the group consisting of:
  - (a) an amino acid sequence shown in SEQ ID NO:2;
  - (b) an amino acid sequence of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said allelic variant is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 (cDNA) or 3 (genomic);
  - (c) an amino acid sequence of an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said ortholog is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 (cDNA) or 3 (genomic); and
  - (d) a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids.
2. An isolated peptide comprising an amino acid sequence selected from the group consisting of:
  - (a) an amino acid sequence shown in SEQ ID NO:2;
  - (b) an amino acid sequence of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said allelic variant is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 (cDNA) or 3 (genomic);
  - (c) an amino acid sequence of an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said ortholog is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 (cDNA) or 3 (genomic); and
  - (d) a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids.
3. An isolated antibody that selectively binds to a peptide of claim 2.

4. An isolated nucleic acid molecule consisting of a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence that encodes an amino acid sequence shown in SEQ ID NO:2;
- (b) a nucleotide sequence that encodes of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 (cDNA) or 3 (genomic);
- (c) a nucleotide sequence that encodes an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 (cDNA) or 3 (genomic);
- (d) a nucleotide sequence that encodes a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids; and
- (e) a nucleotide sequence that is the complement of a nucleotide sequence of (a)-(d).

5. An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence that encodes an amino acid sequence shown in SEQ ID NO:2;
- (b) a nucleotide sequence that encodes of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 (cDNA) or 3 (genomic);
- (c) a nucleotide sequence that encodes an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 (cDNA) or 3 (genomic);
- (d) a nucleotide sequence that encodes a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids; and
- (e) a nucleotide sequence that is the complement of a nucleotide sequence of (a)-(d).

6. A gene chip comprising a nucleic acid molecule of claim 5.

7. A transgenic non-human animal comprising a nucleic acid molecule of claim 5.
8. A nucleic acid vector comprising a nucleic acid molecule of claim 5.
9. A host cell containing the vector of claim 8.
10. A method for producing any of the peptides of claim 1 comprising introducing a nucleotide sequence encoding any of the amino acid sequences in (a)-(d) into a host cell, and culturing the host cell under conditions in which the peptides are expressed from the nucleotide sequence.
11. A method for producing any of the peptides of claim 2 comprising introducing a nucleotide sequence encoding any of the amino acid sequences in (a)-(d) into a host cell, and culturing the host cell under conditions in which the peptides are expressed from the nucleotide sequence.
12. A method for detecting the presence of any of the peptides of claim 2 in a sample, said method comprising contacting said sample with a detection agent that specifically allows detection of the presence of the peptide in the sample and then detecting the presence of the peptide.
13. A method for detecting the presence of a nucleic acid molecule of claim 5 in a sample, said method comprising contacting the sample with an oligonucleotide that hybridizes to said nucleic acid molecule under stringent conditions and determining whether the oligonucleotide binds to said nucleic acid molecule in the sample.
14. A method for identifying a modulator of a peptide of claim 2, said method comprising contacting said peptide with an agent and determining if said agent has modulated the function or activity of said peptide.
15. The method of claim 14, wherein said agent is administered to a host cell comprising an expression vector that expresses said peptide.

16. A method for identifying an agent that binds to any of the peptides of claim 2, said method comprising contacting the peptide with an agent and assaying the contacted mixture to determine whether a complex is formed with the agent bound to the peptide.

17. A pharmaceutical composition comprising an agent identified by the method of claim 16 and a pharmaceutically acceptable carrier therefor.

18. A method for treating a disease or condition mediated by a human proteases, said method comprising administering to a patient a pharmaceutically effective amount of an agent identified by the method of claim 16.

19. A method for identifying a modulator of the expression of a peptide of claim 2, said method comprising contacting a cell expressing said peptide with an agent, and determining if said agent has modulated the expression of said peptide.

20. An isolated human protease peptide having an amino acid sequence that shares at least 70% homology with an amino acid sequence shown in SEQ ID NO:2.

21. A peptide according to claim 20 that shares at least 90 percent homology with an amino acid sequence shown in SEQ ID NO:2.

22. An isolated nucleic acid molecule encoding a human protease peptide, said nucleic acid molecule sharing at least 80 percent homology with a nucleic acid molecule shown in SEQ ID NOS:1 (cDNA) or 3 (genomic).

23. A nucleic acid molecule according to claim 22 that shares at least 90 percent homology with a nucleic acid molecule shown in SEQ ID NOS:1 (cDNA) or 3 (genomic).

```

1  TAAATAACAG CTTTAATGAG CAGCAATTCA TCCCTGCTGG TGGCTGTGCA
51  GCTCTGCTAC GCGAATGTGA ATGGGTCTCG TTTTAAAAAT CCCCTCTCGC
101 CCGGATCCCG GGTGATTCCTG TACATAGTCT TTGGCTTTGG GGCTGTGCTG
151 GTTGTGTTTG AAAAATTCTT GGTGATGATT TAAATCTCTC ATTTCAAAACA
201 GCTGCACTCT CCGACCAATT TTCTCGTTGC CTCTCTGGCC TGGCTGTGAT
251 TCTTGGTGGG TTTTAAATTTG ATGCCCTTCA ATATGTTAG GACGGTGGAG
301 AGCTGCTGGT ATTTTGGGAG GAGTTTTTGT ACTTTCCACA CCTGCTGTGA
351 TGTGGCATTT TTTTAACTCT CTCTCTTTCA CTCTGCTTC ATCTCCATCG
401 ACAGGTACAT TGGGTTACT GACCCCTGG TCTATCCTAC CAAGTTCACC
451 GTATCTGTGT CAGGAATTTG CATCAGCGTG TCGTGGATCC TGCCCTCAT
501 GTACAGCGGT GCTGTGTTCT ACACAGGTGT CTATGACGAT GGGCTGGAGG
551 AATTATCTGA TGCCCTAAAC TGTATAGGAG GTTGTGAGAC CGTTGTAAAT
601 CAAAACGGG TGTGACAGA TTTTCTATCC TTCTTTATAC CTACCTTTAT
651 TATGATAATT CTGTATGGTA ACATATTTCT TGTGGCTAGA CGACAGGCCA
701 AAAAGATAGA AAATACTGGT AGCAAGACAG AATCATCCTC AGAGAGTTAC
751 AAAGCCAGAG TGGCCAGGAG AGAGAGAAAA GCAGTAAAA CCCTGGGGGT
801 CACAGTGGTA GCAATTTATGA TTTTATGGT ACCATATAGC ATTGATTGAT
851 TAATTGATGC CTTTATGGGC TTTATAACCC CTGCCTGTAT TTATGAGATT
901 TGCTGTTGGT GTGCTTATTA TAACTCAGCC ATGAATCCTT TGATTTATGC
951 TTTATTTTAC CATGGTTTA GGAAGCAAT AAAAGTTATT GTAAGTGGTC
1001 AGGTTTTTAA GAACAGTTCA GCAACCATGA ATTTGTTTTC TGAACATATA
1051 TAAGCAGTTG GATAGACGAA GTTCAGGATA CC (SEQ ID NO:1)

```

**FEATURES:**

Start: 16  
Stop: 1051

**HOMOLOGOUS PROTEIN:**Top 10 BLAST Hits:

	Score	E
gi 4505925 ref NP_003958.1  putative neurotransmitter receptor ...	293	2e-78
gi 7657140 ref NP_055442.1  G protein-coupled receptor 57 >gi 6...	252	5e-66
gi 7657142 ref NP_055441.1  G protein-coupled receptor 58 >gi 6...	246	2e-64
gi 3941547 gb AAC82381.1  (AF069546) putative odorant receptor ...	215	6e-55
gi 4028154 gb AAC96118.1  (AF083221) putative neurotransmitter ...	200	2e-50
gi 4028153 gb AAC96117.1  (AF083221) putative neurotransmitter ...	197	1e-49
gi 3646424 emb CAA09599.1  (AJ011370) serotonin 4 receptor [Rat...	179	3e-44
gi 3962388 emb CAA06536.1  (AJ005433) dopamine D1/beta receptor...	176	3e-43
gi 2661757 emb CAA73107.1  (Y12505) 5-HT4 receptor [Homo sapien...	176	4e-43
gi 3326989 emb CAA73108.1  (Y12506) 5-HT4 receptor [Homo sapiens]	176	4e-43

**blast to dbEST:**

ESTs (from GenBank EST division)

	Score	E
gi 7996957 gb AW862937.1 AW862937 MR2-SN0005-110500-001-d09 SN0...	44	0.093

**EXPRESSION INFORMATION FOR MODULATORY USE:**Expression information from BLAST dbEST hit:

gi|7996957|gb|AW862937.1 Human stomach

Expression information from PCR-based tissue screening panels

Human Placenta  
Human Kidney  
Human Skeletal muscle  
Human Liver  
Human Bone marrow  
Human Thymus

FIGURE 1

```

1  MSSSSSLVA VMLCTADVMG SCVFIFFSFG SEVILYIVFG FGAVLAVFGN
51  LIAVMSILHF EQLHSFTDFL VADLAFADFL VCVTVMPFGN VPTVESCWFY
101 GRSFCTHTC CDVAECYSSL EHLCEISIDP YIAVTDPLVY PTFKTVSVSG
151 ITISVSWILP LMYGSAVFTT GVYHDLKEL SDALNCIGP OTVVHONWVL
201 TDFLSEFIPT FIMILLYHNI FIVAPPOAFY IENTGSETES SSEGYKAPVA
251 RRRERKAAKTL GVTVVAFMIS WLETUIDSLI DAFMGFITEA CITEICCWCA
301 YVNSAMNLI YALFYEWFRK AIKVIVTGQV LKNSATMHL FSEHI (SEQ ID NO:2)

```

**FEATURES:****Functional domains and key regions:**

[1] PDOC00001 PS00001 ASN\_GLYCOSYLATIONN-glycosylation site

Number of matches: 3

- 1 4-7 NSSL (residues 4-7 of SEQ ID NO:2)
- 2 19-22 NGSC (residues 19-22 of SEQ ID NO:2)
- 3 334-337 NSSA (residues 334-337 of SEQ ID NO:2)

[2] PDOC00005 PS00005 PKC\_PHOSPHO\_SITEProtein kinase C phosphorylation site  
245-247 SYK

[3] PDOC00006 PS00006 CK2\_PHOSPHO\_SITECasein kinase II phosphorylation site

Number of matches: 4

- 1 109-112 TCCD (residues 109-112 of SEQ ID NO:2)
- 2 237-240 SKTE (residues 237-240 of SEQ ID NO:2)
- 3 241-244 SSSE (residues 241-244 of SEQ ID NO:2)
- 4 279-282 SLID (residues 279-282 of SEQ ID NO:2)

[4] PDOC00007 PS00007 TYR\_PHOSPHO\_SITETyrosine kinase phosphorylation site  
92-99 RTVESCWY (residues 92-99 of SEQ ID NO:2)

[5] PDOC00008 PS00008 MYRISTYLN-myrystoylation site

Number of matches: 3

- 1 42-47 GAVLAV (residues 42-47 of SEQ ID NO:2)
- 2 150-155 GICISV (residues 150-155 of SEQ ID NO:2)
- 3 189-194 GGCQTV (residues 189-194 of SEQ ID NO:2)

[6] PDOC00210 PS00237 G\_PROTEIN\_RECEPTORG-protein coupled receptors signature  
118-134 SSFLHLCFISIDRYIAV (residues 118-134 of SEQ ID NO:2)

**Membrane spanning structure and domains:**

Helix	Begin	End	Score	Certainty
1	33	53	2.047	Certain
2	71	91	1.433	Certain
3	109	129	1.228	Certain
4	143	163	1.658	Certain
5	204	224	2.061	Certain
6	257	277	1.672	Certain
7	283	303	1.273	Certain

## BLAST Alignment to Top Hit:

>gi|4505925|ref|NP\_003958.1| putative neurotransmitter receptor  
 >gi|7441617|pir|JC5832 neurotransmitter receptor - human  
 >gi|2465432|gb|AAC39581.1 (AF019118) putative  
 neurotransmitter receptor [Homo sapiens]  
 length = 337

Score = 293 bits (742), Expect = 2e-78  
 Identities = 144/331 (43%), Positives = 213/331 (63%)  
 Frame = +1

Query: 40 CYANVNGSCVKIPFSGSRVILYIVFGFGAVLAVFGNLLVMISILHFKQLHSPTNFLVAS 219  
 CY VNGSC + + G ++++Y+ G ++ V GN+ V ++ +EK LH+PTNFL+ S  
 Sbjct: 17 CY-QVNGSCPRTVHTLGIQLVIYLTCAAGMLIIVLGNVFVAFVSYFKALHTPTNFLLLS 75

Query: 220 LACADFLVGVTVMFPFSMVRTVESWCYFGRSFCFHTCCDVAFCYSSLEHLCFISIDRYIA 399  
 LA AD +G+ V+P S +R+VESCW+FG C HT D FC +S+FHLCFISIDR+ A  
 Sbjct: 76 LALADMFGLLVPLSTIRSVESCWEFGDFLCRLHTYLDTLFCLTSIFHLCFISIDRHCA 135

Query: 400 VTDPLVYPTKFTVSVSGICISVSWILAPHVQRVLCSTQGVYDDGLEELSDALNCIGGCQT 579  
 + DPL+YF+KFTV V+ I W + P L V + L + + + C+G CQ  
 Sbjct: 136 ICDEPLLYPSKFTVRVALRYILAGWGV-PAAYTSLFLYTDVVETRLSQWLEEMPCVGCQQL 194

Query: 580 VVNQNWVLTDFLSFFIPTFIMIILYGNIFLVARROAKKIENTGSKTESSSESYKARVARR 759  
 ++N+ W +E FF+P IMI LY IF+VA RQA++I T SK+ A A+  
 Sbjct: 195 LBNKFWGWLNFPLFFVPCIMISLYVKIFVVATRQAQQT-TTLSKS-----LAGAAKH 246

Query: 760 ERKAAKTLGVTVVAFMISWLPYSIDSLIDAEMGFITPACIYEICCWCAYYNSAMNPLIYA 939  
 ERKAAKTLG+ V +++ WLP++ID+++D+ + FITP +++I W AY+NSA NP+IY  
 Sbjct: 247 ERKAAKTLGIVVGIYLLCWLFETIDTMVDSLHFIPTPLVFDIFIWFAYFNSACNPIIYV 306

Query: 940 LEYPWFRKAIKIVITGQVLKNSSATMNLFESE 1032 (residues 14-343 of SEQ ID NO:2)  
 Y WERKA+K+ ++ +V + T++L+ E  
 Sbjct: 307 ESYQWFRKALKLTLSQKVESFQTRTVLDLYQE 337 (SEQ ID NO:5)

>gi|7657140|ref|NP\_055442.1| G protein-coupled receptor 57  
 >gi|6739496|gb|AAF27279.1|AF112461.1 (AF112461) G  
 protein-coupled receptor 57 [Homo sapiens]  
 Length = 343

Score = 252 bits (636), Expect = 5e-66  
 Identities = 124/298 (41%), Positives = 184/298 (61%), Gaps = 1/298 (0%)  
 Frame = +1

Query: 139 VFGNLLVMISILHFKQLHSPTNFLVASLACADFLVGVTVMFPFSMVRTVESWCYFGRSFCF 318  
 +FGNL++M+SI HFKQLHSPTNFL+ S+A DFL+G +MP+S++R+VESCWYEG FC  
 Sbjct: 46 LFGNLVIMVSISHFKQLHSPTNFLILSMATTDLLGFEVIMFYSIMRSVESCWYFGDGFCK 105

Query: 319 FHTCCDVAFCYSSLEHLCFISIDRYIAVTDPLVYPTKFTVSVSGICISVSWILAPHVQRV 498  
 FHT D+ +S+FHLC I+IDR+ AV PL Y TK T S ++ W +  
 Sbjct: 106 FHTSFDMMLRLTSIFHLCSIAIDREYAVCYPLHYTTKMTNSTIKQLLAFCWSVPALEFEG 165

Query: 499 LCSTQGVYDDGLEELSDALNCIGGCQTVVNQNWVLTDFLS-FFIPTFIMIILYGNIFLVA 675  
 L ++ G++ + C C N+ W F + FF P IM+ +YG IF+V+  
 Sbjct: 166 LVLSEADV-SGMQSYKILVACFHFCAITENKFWGTILETTCTETPGSIMVGIYKGFIVS 224

Query: 676 RROAKKIENTGSKTESSSESYKARVARREPKAFTLGTVTVVAFMISWLPYSIDSLIDAEM 855  
 ++ A+ I + T+ + + + ++ ++PKAFTLG+ + F+ WLP + LID ++  
 Sbjct: 225 KQHAPVISHVPEHTKGAVKHLSK--FYPDYAAKTLGIVMGVFLACWLFCLAVLIDFYL 292

Query: NIA GFTTPACTYEICGWCAYTUSAMWPLIYALFTFWEPFAIKVIVTGVLENGSATMULESE 103  
(residues 47-343 of SEQ ID NO:2)

YTF I I I W YHS NPLIF E PWEIFA F IVHII I G T NLF E  
Subject: NIA DYSTPLILDLLVWIRYFNSTCNPLINGFTNPWFQKAFKYIVGSEIFTSRGETANLFPE 441 (SEQ ID NO:6)

Hammer search results (Pfam):

Model	Description	Score	E-value	N
PF00001	7 transmembrane receptor (rhodopsin family)	208.8	4.6e-65	2
CE00516	CE00516 SEROTONIN_RECEPTOR	168.2	1.3e-46	3
CE00267	E00267 Octopamine_receptor	147.9	5.7e-41	4
CE00503	CE00503 ADRENERGIC_RECEPTOR	132.6	4.5e-36	4
CE00510	CE00510 HISTAMINE_RECEPTOR	111.3	1.2e-31	3
CE00177	CE00177 ADENOSINE	66.5	1e-17	2
CE00507	CE00507 DOPAMINE_RECEPTOR	66.5	6.3e-18	3
CE00323	E00323 kappa_opioid_receptor	60.4	9.4e-18	2
CE00326	E00326 mu_opioid_receptor	46.0	7.3e-13	2
CE00513	CE00513 NEUROPEPTIDE_Y_RECEPTOR	38.7	2e-10	2
CE00336	E00336 orexin_receptor	36.8	7.2e-10	2
CE00328	E00328 tachykinin_receptor	29.8	1.5e-07	2
CE00325	E00325 lysophosphatidic acid_receptor	29.8	7.3e-09	2
CE00530	CE00530 CHEMOKINE_RECEPTOR_TYPE_4	27.9	2.9e-08	2
CE00511	CE00511 MELANOCORTIN_RECEPTOR	18.2	0.0002	2

```

1   CTTCAGGAAAG ACAATAATAT AATAATAA'A ATATTTTCTT CACTCTGCAG
51  TGTCTTTTACA TTCTAGGGTT GCGAA'ATTA CTGAGGATTC TCTTCCCAT
101 TTCCAGTTTC CTGTTTCATTA TTCTTATTTT TTTGACTGCT TTTAGCATCG
151 AGAGCA'AAA GGC'CACTTAC CAG'AAATT' AAA'AAATGC GTAGT'AGAG
201 AGAGAGG'AT CACTGCCCAT TTCT'ATGTG GATGCAGACA CATTGCAGAT
251 CTCTTTCC'AG TAA'AAAT'TC T'GAGAAGAG GAT'GGTCTT TCCACLAGCA
301 TCTCAGAAAT GCGGGTGTGT CTAAA'AG'A TCTCGTTCTT TAATGCT'TTC
351 ATGCAATATA TTTTATCAAT C'CAAGTTTC C'CTCACTATG TATTATAATA
401 ATTTCTGTCT GTTGGTAACC AATGCAGATG GAAAAT'GAT TCTTAACAGA
451 AGAGAAAGAG CCAAGTATTC ATGCTTACTA TTTACACCCT ATTGTATCTT
501 TGTAACAAAA ACCCGGGTGG CTAAGTTATG ATTGGGAACA AGGGAATGGT
551 TCAAGTCTAT GCACTAAGGA AAAACAAATC TTTGGCCTAA AACAAATATG
601 ATAATAGAA' TTAATATAGA GTAGAGACCT GTTTTGTAGA ATAAC'TTCC
651 TAGTAATCAC TGTTGAAAAAT AATCATACTA GTTCACACCG CGCACTACAG
701 GGATTCCATC GAGGGATTTT CCCATTGAAG GCATTTATTT AGCTAAAAGG
751 ACTTCACTCT TAAGGCGGTA ATGCAGGACA GATAACAGAG ATAAAGATAA
801 CAGGAGGTGA TCTTTCAGCT CCATAATTAC ATTCCATATC AGCGACTGTT
851 GCACAGAGAA ACTCAAAAGG TAAAAATAAA ATATGAAAGG ATATTTAAAA
901 TCAAAAAGGAA TTTTATCAAA TTAAGAGCAT GAGACATTTA TCAGTTGAAA
951 CAATCTCCAA TAATCTTGTG CAATATAATT TTTGTCAAAT TTTATTTTGT
1001 CATAAACATT TGGGATTTAT AATAAAAATG GAAACTTGAA AAATTATATT
1051 AGAGATAATA TCTGATCATT TCCTCTGGCA TCCTGGTGAA TATGTGTTTT
1101 TTTCCGCAGG AGCACTGAAA ATCAGGAACA ATCCTGTATT TTTTGTGATA
1151 ATCAACAAGG ACAAAACTTC TCCATATGTA AATAACAGCG TTATGAGCAG
1201 CAATTCATCC CTGCTGGTGG CTGTGCAGCT GTGCTACGCG AACGTGAATG
1251 GGTCTCTGTG GAAAAATCCC TTCTCGCCGG GATCCCGGGT GATTCTGTAC
1301 ATAGTGT'TTG GCTTTGGGGC TGTGCTGGCT GTGTTTGGA AACTCCTGGT
1351 GATGATTTCA ATCCTCCATT TCAAGCAGCT GCACTCTCCG ACCAATTTTC
1401 TCGTTGCCTC TCTGGCCTGC GCTGATTCT TGGTGGGTGT GACTGTGATG
1451 CCGTTTCAGCA TGGTCAGGAC GGTGGAGAGC TGCTGTGATT TTGGGAGGAG
1501 TTTTGTACT TTCCACACCT GCTGTGATGT GGCATTTTGT TACTCTTCTC
1551 TCTTTCACTT GTGCTTCATC TCCATCGACA GGTACATTGC GGT'TACTGAC
1601 CCGCTGGTCT ATCCTACCAA GTTACCCGTA TCTGTGTCAG GAATTTGCAT
1651 CAGCGTGTCC TGGATCCTGC CCCTCATGTA CAGCGGTGCT GTGTTCTACA
1701 CAGGTGTCTA TGACGATGGG CTGGAGGAAT TATCTGATGC CCTAAACTGT
1751 ATAGGAGGTT GTGAGACCGT TGTAAATCAA AACTGGGTGT TGACAGATT
1801 TCTATCTTTC TTTATACCTA CCTTTATTAT GATAATTCTG TATGGTAACA
1851 TATTTCTTGT GGCTAGACGA CAGGCGAAAA AGATAGAAAA TACTGGTAGC
1901 AAGACAGAAT CATCTCAGA GAGTTACAAA GCCAGAGTGG CCAGGAGAGA
1951 GAGAAAGCA GCTAAAACCC TGGGGGTAC AGTGGTAGCA TTTATGATT
2001 CATGGTTACC ATATAGCATT GATTCATTAA TTGATGCCTT TATGGGCTTT
2051 ATAACCCTG CCTGTATTTA TGAGATTGCT TGTTGGGTGT CTTATTATAA
2101 CTCAGCCATG AATCCTTTGA TTTATGCTTT ATTTTACCCA TGGTTTAGGA
2151 AAGCAATAAA AGTTATTGTA ACTGGTCAGG TTTTAAAGAA CAGTTCAGCA
2201 ACCATGAATT TGTTTCTGA ACATATATAA GCAGTTGTAT AGACGAAGTT
2251 CAGGATACCT TTAATAATTAC CAAGCGAAAT GAGTTTITAA AAATCAAGTA
2301 AGACTATGAA TGAATAGCAA ATAAATTGCT CTTCAAATGA AAAACAAATC
2351 AATGTTTTTC AGTCTTGTTA AGATGTGCAC TTTCTGTGCC CTTCTGCAAA
2401 AGTATTACT TGGCTAACAA ATGTTAAATT CCTATTGTG AACTGCTTTA
2451 GAGCTCAGCA TATCCCACTC CTTGCAGACA CTTTITGTCT TTTAATCCAT
2501 TGACTCTTCC CTCTGCTCTG GTATTTTTC TAAAAATATT TGT'TTTTTT
2551 TTTTATTTA TTCCCTTTC TCTTTCTTT ACAAGCTTT CTACTCTTTC
2601 CCAGCCTGCC AAAAAATTCA TTTGTGAATA GCCTTTATCA AATTATTGGT
2651 TTCTTTTGTG TTGGT'ATTT TACCACAGGA GTCCTTTTAG GTATTAATT
2701 AATTTATTCA ATCTTGGGAG AGATCTCAGG GTGTATGGGG CAATTTGCAA
2751 ATGAAGACAT CATCTTGACC AGGCTGTGT AATTGTCAAA CCAGTTACTG
2801 TCATTCITGT AATTATTTCC TCCCCAAAG TGGGAAGCAG AAGCCACTGT
2851 ACTTCCGAGA ATGATGTTAG GATGATTATT TGGCTGCTGT TCTTGCTATT
2901 GCACAAAACCT GTTTAAAGAG TTTGGTATGAA TAGAGCCCTG TGT'TACATTA
2951 TTCAGTTTAT ACACATTGAA TATTACTTGT TCCTTTAGGG AGGATATCTT
3001 TCAAGTGCAG TCTCTAGCTT TCTTTTCTTT TTTTITCTAT ATTTAAACTT
3051 AATTACAGCA AGGAATTTGC AAGATTAGAA GCCATGTGGA ATATACATCA
3101 ATGAGAAGCA TTCAGGTATT CATCCATGTT TTTTCCATTT ACCAAACATG
3151 AAACCTGTGC CTATATTCTA TGAAATCAG TGCTAGATGC CTTAGACACA
3201 UG'ATAACAT CCCATTTT' TCTTAAATA GCTGTGACTC TGGCAAGAAG
3251 CAATGTTGCT CACTGAAAA TTTAAAAAGG GCGAACACTA GCTCAACAG

```

FIGURE 3, page 1 of 4

```

3301 GTAATTAAGG TTCAATATCA GTAGTAGTAA GGCATGTGCU TATTGTGTGT
3351 TCTTGACATT ATGTAATGAG AATGGCTTTT A'CTCTATGT' CCTTTCTTCC
3401 CCAAAATCCAT AACCCCATG TAATCATGAG AAAAATGTCA GACGAAACTT
3451 TATCGGGAAT ATTCTGCATA ATATTGATC AGTATTCTC' AAAACTGTCA
3501 GTCATCAAAA ATAAAGTATG A'AAACTTTC ATGATCTACA GGAACCTAAG
3551 AAGACATGAC AACTAAATTT' ATATGTCAT C'ATAATUGA AAGCTAGAAA
3601 GAAAAGGGAC ATTAGCGGAA G'GAGGAAAT C'GAATAATG AATGGAAATT
3651 TTATTGCTAT ATTGATAACA ATATTGATC ATTAGT'ATC ACAAATGTAC
3701 TATATGAGTT TAAGATGTTA ATGAGAACT TCTTGCAAGG TATATAGGAA
3751 TTCTCATTAC TATCTTTGCA ATTTTTCAGT AATTCTACAA CTATTCTGAA
3801 ATTAAAAGTT TATTCAAAA ATATAGAGTA CACAATTCCT GCTTGATAAA
3851 GTTCTAGCC TGTCTATGTG AAGACAGCAA AGCACTTATC CTTACAGTCA
3901 TTCATTTATT CATCTGAAT ATATCTTTGA AGACTGAGTG TGTACTAGAC
3951 TCTTGGTTCA GTGTGATCAG GAATAGAAAA CCAGGAACCT AGAATATTTT
4001 GTGGCAAAAC CCAAAATACC AGTAATTAAG ACTTGGAATG CATGGGAATT
4051 TAAGCTATAA AAGGCTGTGT TTAAGGAACA CAGGAGAAAG GAGAAATTCAG
4101 ACCTGGATGG AAAATGAAGG AGATGTATTA AAGAAGTGGC ATTCAAGTAG
4151 GGCCTTAAAT TTAAAGAAGG ATTTTGTAG GAGGGAAAGG ATGGGAAGCG
4201 ATTTTCAGGC ATGAGCAAAG AAACGTAGAA AGTGCAAAGT GTTTAGGGAA
4251 TATGAAAAA AAACAAC TAGCTGGGCGTG GTGGGTCACG CCTGTAATCC
4301 CAGCACTTTG GAGGGCCAAG GCGGGTGGAT CACAAGGTCA AAAGATCGAG
4351 AACAGCCITG CTAACAGGGT GAAACCCCGT CTCTACTAAA AATACAAAAA
4401 TTATCTGAT GTGGTGGCAC GTGCTGTAG TCCAGCTTC TCGGAGGGCT
4451 GAGGCAGGAG AATCTCTTGA ACCTGGGAGG TGGAGGTTGC AGTGAGCCGA
4501 GATCATGCCA CTGTACTCCA GCCTGGGTGA CAGAGTGAAA CTCTATCAAA
4551 AAAAAAAGA AAAAAAGAA AAAAAAGAAA GAAAGAAAAT AAAACAAC TA
4601 AACCAACCAC AAGAAGCAAG AAGTAGTAC GCTTTTAAAC CCTCCCAAGG
4651 TTGGCATCCA AACCTGCAC CTCTACTTCT CCTGGGCATC CTCCATTGTG
4701 GTTGGGAGAC ATTCTCCCT CTCTGCTCAA GTTTCAGCTC CCATAATTGT
4751 TTTCTAAGAA ACATTTCTCA AATGAGGCTT TACAAAACAG TCATCACATA
4801 AAATGCTCCA AGGAAAAAGA TTCTGATTC AACAAATGTT TGGAACTGTT
4851 GCATACTCTT TTCTGTTCTT GGAGAACACT GTATATTGGC ATATTAAAGA
4901 CTCTGAGAAG TCCTGTTTTA GCAAAAACCT GTCCAATTTT GTTTAAATGT
4951 GCATTCTAAA CATTTATTAA ACCATGGGTA CTCTTTTGAT ATGAGGAGCT
5001 CAATAACAGA GCTATTGTCC AAGGAAAAATA TTAAGGAAC ACCATCTCTA
5051 TCGTTGATTT GGTTCCTACC TAATGTATTA TTAATCTGT ATTGGTCTTT
5101 TGGTCTTTCA CATACAATAC ACTTCATTC AATTGTATTT CTAAAAGGTA
5151 GAGGTGTTTT TCCAACCCAT GGTATAATAA TGAGTAAGCA CTCATAACAT
5201 GTTTTTTTTT GTCAATTATG ATGTATAAGA TAAATTGTAC AGTATGTAAA
5251 ATGGGATAAA TTATGTGACT TTGAAGGAGG GACTGGATGC TGCAGACTGA
5301 AAAATCTCAG AAGGTCCAT GGAGAACTTA GAATATAATA CCAGCTAAGC
5351 AGTGGAGGAT TGGTTTAAAT AGAAAAACA ATAGTAGAAA AGGAATTTCT
5401 AGGCAGAATA AAAATCTCAT GAAAGGTATA AATTTAGTGG TGCATCAAAT
5451 GCAATTAAGC ATACAAAAAA GGATAGCCAA TAAGATCAGT CGGCCATAAG
5501 CACACCATT GGGTAAGAGA GTCACAATCA ATCTATCCAT CAATCAACAT
5551 ACTATTTTAA GCCCTATATC TGCACTGTCC AGTATGGTAG CCATGAGCAA
5601 CATGTGTTTA TTGAGGACTT GAAATGTGGC TAGTCTGAGC TGAGATATTC
5651 TATAGGTAGA ATTTATATAC CAGATTTCAA AGACAAACAA AAGAATGTAA
5701 GATGCTCTTT TTTAAATAT TGATTACATG TTGAAATTAT CAATTTTGGG
5751 ATGTATTGGG TTAATAAAAA ATATGTTATT TAGATTAATT TCTCTTTTCT
5801 CTTTTTACTT TTTAAATGT GGCTACTAGA AAAATGTAAA ATTATGTATG
5851 TAGCTTAAAT TATATTTCTA TTGGACAGCA CTACTCTAGA GAAAACAAAA
5901 ATGAGCCATA GGACAATTCT AGCCCTCCAG GACTTAAAAA TCAAGATGGG
5951 GAGAGAATGC ATGAACATAA ACAATGAAGT AAATATATAT GAACTATGGT
6001 AAAAGTTAAA TAATATTTAT TTAGCAATTG ATGTTTAAAA ACAGAGGTAC
6051 AAAACTCATA TTAATCTTAT AGTCTGGTCA TTTTATAAAT GAGAAAATTG
6101 GGACTCAGAG AGAAATAAAT TAACTTGAT GAAATATATC AGCTAGTAGG
6151 CTAGGTGCGG TTGCTCACGC CTGTAATCTC AGCACTTTGG GAAGCTGAAG
6201 TGGGAGGATC ACTTGAGTTC AGGAGTTTGA TACCAGCCTG GGCACATAG
6251 TGAGACCTTG TCTGTACTAA AAATGAAAAA GTTAGCCAGG CGTGGTGGTG
6301 AATGCCTGTA GTCCAGCTA CTCAGGAGGC TCAGGTGGGA GGATCATTG
6351 TACACAGGAG TTTGAGGCTG CACTGAGCAG TGATCGCATC TAGAAACAAA
6401 GTGAGATTCT GTCTCAAAAA ATAAAAAGTT ATACAGTTAG CAAAAATCT
6451 TTGCCATACT TTGAACCAA ATTATTTGAA TTCTAAGCTC AATTTTTTTT
6501 CTCCACATGG AAATGAGAGT TTAGGACAAA CAATAAGGGA TATTACAAAG
6551 AAGTACAGTT AAATAAATG' TATCTACAAG AAGATATTTA GCATTTAGAG

```

FIGURE 3, page 2 of 4

```

6601 TTTCTCTCAT AAGTCAGTGG TTCTTGATAA TTTTLAGATC ATAGTCACAT
6651 TGAAATATGC TGAAATCTAT CTATTCTTTT TTAGAAAAA TGCAACAAAT
6701 ACATATATCA CAATATTTAG TGTATATTTC TGGGGGTCC ATAACTTTT
6751 GGGCAATTA CAGGTCATGG ATAACTTTT TTAAGTTGG GCATAGACTA
6801 GACTTGGCTG AAGTGAAAAC GACTTCAAT AA TCTGTGG CTTAACAAA
6851 AAAAGTTTTA TTCTCTGCTC ATGTGAATTT CATATGAGT CTGAGAGAGT
6901 ATCAGGGCAA TTGTCTCTCA CATAGTTCAG GTTCTTTTGA TTTCTAGGCT
6951 CATCTTTTTC AACAGAGAGC TTCTATACCT TAAGCTGAAA GAACACATGA
7001 ACTTTGACAA CTATTAGCCA GAACCAATTA GACAGTCCAC GTAATGGCTT
7051 GAAAAACACA GGCAGATAAG CACAATGTTT GCTGCACACA AAGGCTCTTT
7101 CCAACACTCG TTTTACTGGA TGGGACATCA CATGTGTGTA ATGATGTATC
7151 TCTCAGGGTT TCAATTTGGC AGAAAATGTT TTAAGTTCAT TAGTGTATT
7201 TTTAATCAAT ATTAACTCTA AGTGAGATAG TTGCTGGCTT CGGCTGGCTG
7251 ACTCAAGTAT GTTAGAGTCA AGGATGCTGT ACAGATTTTC CTGATGCTTG
7301 TCTAATGGTT CCAAGTGAC TACAGGAGTT CCAGCCAAAT CACACATGTT
7351 CCTGGAAATA GGGAGGAGGA AGACCTAGGA AGAGGGGCTC TCTGAAGCCC
7401 TACTTGACAA CTTCAGTTTC CCCAAGGGAG AGAAGATTCT GATGCTATGG
7451 AGGAAATTAA CCCATTGGTT GTTAGGTGAG AAATAAGCAT TTCTGCCACA
7501 TGAAGTAATC TGGAAATGA AATCCAACAA GTGAAAAATA AACTTCTTAC
7551 CAAATCTCTC CACAGGTATT TGCTGTATAA ATCCATAAGG AAGTGAAGT
7601 AGAAAAAGAG AATGGAAAAA ATAACAGGTT TTCTCAAAGA TCTCTATACC
7651 ATCTTTTTCT TAACTTCTC CTTTTGTATT ATTTAGTATT AATTTTTCAG
7701 CCAATGAACA TGTAATATAT ATGTGTTACA TAGTAAATGC CCTGTTGACA
7751 ATGCAGAAGT GATGAGAATG AATGAGAETC AATCGTTTTA GTAGAGTTTT
7801 CAATATTTCC CAAAAGGTAG TGGTTACAAG CAGAGCCAGA CAGCCAGTCC
7851 TTTTATGGGA CAAAGATATC TTGCTAGAGA TCACACAGTG GGTGAGCATC
7901 AGGGACAGAG TCCCCAGAAT TTGCAATAGC CTGGTTGTTA TTGCTCTGGA
7951 GCAATCAGTA GAACATGTA AAGGCATATT TTTAATTTT ACATTTCAAG
8001 GTACATGTGC AGGATGTGCA GGTTTGTATC ATAGGTAAAC ATGTGCCATG
8051 GTGGTTTGCT GCACCTATCA ACCCATCACC TAGGTATTAA GCCCAGCATG
8101 CATTAGCTAT TTTCCCTAAT GCTCTCTGCC CCCACCTTAC CCTCTTTCAA
8151 CAGGCCCCAG TTGTGTATGC TCCCTTCTT GTGCTCTGT ATTCTCATFG
8201 TTCAGTCCTC ACTGAAGAAT CAATATCATG AAAATGGCCA TATTGCCCAA
8251 AGCAATTTAT AGATTCAATG CTATTCCCAT TAACTACCA TTGACATTCT
8301 TCACAGAATT AGAAAAAAA GATTTCAAAA TTCATATGGA ACTTAAAAA
8351 AGCTCGTATA GCCAGGCCAA TCCTAAGCAA AAAGAACAAA ACAAAAGAGG
8401 CACCAAGCGA CCCAACTTCA AACTATACTA CAAGGCTACA GTAACCAAAA
8451 CAGCATGGTA CTGGTACAAA ACCGGCACAT AGACCAATGG AACAGAATAG
8501 AGAATCTAGA AATGAAAACA TACATCTAGA ATCATCTGGT CTTCAACAAA
8551 CTTGACAAAA AAACAAGATA TTGGGAAAGT ATTCCCCATT TAATAAATGG
8601 TGCTGGAAGA ACTGGCTAGC CATATGCAAA AAAATTGAAA CTGGGCCCCCT
8651 TCCTTACATC CTATACAAGA ATTAACCTCA GACAGATTAA AGACTTAAAT
8701 GCAAGAACAA TTAATATTTC ACTAGTAGGG CTGCCCTCTA CCAGATGGCT
8751 AATGGAGTCA CGATGCAGAG CTATGAGATG GAGGGCAGGG GATGCTATGG
8801 CTAATTTTAA CCACAGCAGC AAACACAGAA AAACCCACTA GGTCTGTATG
8851 ACTCCTGACC AGCCCCAGCA TCAGATCTTG GTCAGTGTGG GCTATGGTGA
8901 ATTCTAATTT CAAAACCCAA AGCCTAATTT CTGTTGTGTT TGGAAATAAA
8951 TTCTAACTCT GTGATTCTGA TCTATGAGGC TTTGCATAGT CTTAGCCCCG
9001 CACAACCTCT TACCCACTAC CTATTTCTGT CTCCCTTTAC TTGTTATGCT
9051 CCAATATAT TTTGTCCAAT CCAGCCCCCT GGCTACCCCC CACAGGATGC
9101 CTCAGGAGCT GTGCACTGGC TATCCCATCT GTTGACTAG GTCGCTCAGG
9151 AGACTCGCAC AGGGTTTTTC ATCTGTTGGA TCACTCAGTC CTCAGATCTT
9201 CACGGAGCTG GTTCTTTACA CAGGTCTCAG CTTTAACATC GCTCCCTCAG
9251 AAAAATCAAG ATCTCGGCTA ATGTTGTTAT CCATGTTTFA TTCTTTTACT
9301 CACCTTGTTT TTATATCATT TCCTTCATGG TACATATCAG AATGTGTTAC
9351 AATCTTATTC ATCTGTTTAT TTTCTGTGT TTTAACTGTC TGTCTCTTAA
9401 TGACATGTAA GCTGCAGGAG GTCAGATACT TGCTGAAGTA TCACTATGAG
9451 TAAATCAGAC AGTTTGTACT GGTGTTTTAT TTCTTTGCTC CTATGTTGTT
9501 GTTTTACTTT GGTCACTTGA GTAAATAAAT GAGTGAATAA ATAAATAGA
9551 AATAGATTCC CCAGCATTGG GAGGATACAT TAAATGTATT CTTTTTTTTT
9601 TTTTAAAGT TCTGGGGTAC ATGTGCTGGA TGTGCAGTTT TCTTACATAG
9651 GTAAATGTGT GCCATGGTGG TTTGCTGCAC CTATCAACTC ATTACCTAGT
9701 TATTAAGCCT GAAAAAATGC ATTCTTTTTA TAAGCTTTTT TGGGAGGGG
9751 CAGGGTCTTG CTGTGACCTA GGTGCGGTA CAGTGGCATG ATCATAGCTC
9801 AATGCAGCTT CAAACTCCTG GGTTCAGGTG ACACTCCCAT GTAGCTTGGG
9851 CTACAGGCGT GTCCGACCAT GCTTGGCTAA TTTTAAAAA AAATTTATTT

```

FIGURE 3, page 3 of 4

1001 TTGTAGAAAA GGGATCTCAT TTTTGTGCC AGGTTGGTCT TAAACAC (SEQ ID NO:3)

## FEATURES:

Start: 1193

Stop: 1217

## MAP POSITION:

RH mapping panel:

#	SHGCNAME	CHROM#	LOD_SCORE	DIST_(cRs)
1	SHGC-1836	6	11.84	10
2	SHGC-20379	6	9.36	17
3	SHGC-62933	6	8.59	22
4	SHGC-22	6	8.59	22
5	SHGC-12753	6	8.53	25
6	SHGC-8456	6	7.87	27
7	SHGC-34762	6	7.84	30
8	SHGC-12805	6	7.82	27
9	SHGC-1877	6	7.71	20

## ALLELIC VARIANTS (SNPs):

Position	Major	Minor	Context
1,711	g	t	gaacagttcagcaaccatgaatttgttttctgaacatatataagcagttg[g/t]ata gacgaagttcaggataacctttaaaattaccaagcgaaatgagttttt (SEQ ID NO:4)

POSITION	Allele 1	Allele 2		Position	Protein
1,711	g	t	Exon	73	Y <u>Ter[und]</u>

## SEQUENCE LISTING

<110> PE CORPORATION (NY)

<120> ISOLATED HUMAN G-PROTEIN COUPLED  
RECEPTORS, NUCLEIC ACID MOLECULES ENCODING HUMAN GPCR  
PROTEINS, AND USES THEREOF

<130> CL000899PCT

<140> TO BE ASSIGNED

<141> 2001-10-24

<150> 09/694,821

<151> 2000-10-24

<150> 09/781,559

<151> 2001-13-02

<160> 6

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 1082

<212> DNA

<213> Human

<400> 1

```

taaataacag cgtaaagag cagcaattca tccctgctgg tggctgtgca gctgtgctac 60
gcgaacgtga atgggtcctg tgtgaaaatc cccttctcgc cgggatcccg ggtgattctg 120
tacatagtggt ttggcttttg ggctgtgctg gctgtgtttg gaaacctcct ggtgatgatt 180
tcaatcctcc atttcaagca gctgcactct ccgaccaatt ttctcgttgc ctctctggcc 240
tgcgctgatt tcttggtggg tgtgactgtg atgcccttca gcatggtcag gacgggtggag 300
agctgctggg attttgggg gagtttttgg actttccaca cctgctgtga tgtggcattt 360
tgttactctt ctctctttca cttgtgcttc atctccatcg acaggtacat tgcgggttact 420
gacccctggg tctatcctac caagttcacc gtatctgtgt caggaaattg catcagcgtg 480
tcctggatcc tgccctcat gtacagcggg gctgtgttct acacaggtgt ctatgacgat 540
gggctggagg aattatctga tgcctaaac tgtataggag gttgtcagac cgttgtaaat 600
caaaactggg tgttgacaga ttttctatcc ttctttatac ctacctttat tatgataatt 660
ctgtatggta acatatttct tgtggctaga cgacaggcga aaaagataga aaatactggg 720
agcaagacag aatcatcctc agagagttac aaagccagag tggccaggag agagagaaaa 780
gcagctaaaa ccctgggggt cacagtggta gcatttatga ttctatgggt accatatagc 840
attgattcat taattgatgc ctttatgggc tttataaccc ctgcctgtat ttatgagatt 900
tgctgttggg gtgcttatta taactcagcc atgaatcctt tgatttatgc tttattttac 960
ccatgggtta ggaaagcaat aaaagtattt gtaactggtc aggtttttaa gaacagttca 1020
gcaaccatga atttggtttc tgaacatata taagcagttg gatagacgaa gttcaggata 1080
cc

```

1082

<210> 2

<211> 345

<212> PRT

<213> Human

<400> 2

```

Met Ser Ser Asn Ser Ser Leu Leu Val Ala Val Gln Leu Cys Tyr Ala
1           5           10           15
Asn Val Asn Gly Ser Cys Val Lys Ile Pro Phe Ser Pro Gly Ser Arg
20           25           30
Val Ile Leu Tyr Ile Val Phe Gly Phe Gly Ala Val Leu Ala Val Phe

```

35	40	45
Gly Asn Leu Leu Val Met Ile Ser Ile Leu His Phe Lys Gln Leu His		
50	55	60
Ser Pro Thr Asn Phe Leu Val Ala Ser Leu Ala Cys Ala Asp Phe Leu		
65	70	75
Val Gly Val Thr Val Met Pro Phe Ser Met Val Arg Thr Val Glu Ser		
85	90	95
Cys Trp Tyr Phe Gly Arg Ser Phe Cys Thr Phe His Thr Cys Cys Asp		
100	105	110
Val Ala Phe Cys Tyr Ser Ser Leu Phe His Leu Cys Phe Ile Ser Ile		
115	120	125
Asp Arg Tyr Ile Ala Val Thr Asp Pro Leu Val Tyr Pro Thr Lys Phe		
130	135	140
Thr Val Ser Val Ser Gly Ile Cys Ile Ser Val Ser Trp Ile Leu Pro		
145	150	155
Leu Met Tyr Ser Gly Ala Val Phe Tyr Thr Gly Val Tyr Asp Asp Gly		
165	170	175
Leu Glu Glu Leu Ser Asp Ala Leu Asn Cys Ile Gly Gly Cys Gln Thr		
180	185	190
Val Val Asn Gln Asn Trp Val Leu Thr Asp Phe Leu Ser Phe Phe Ile		
195	200	205
Pro Thr Phe Ile Met Ile Ile Leu Tyr Gly Asn Ile Phe Leu Val Ala		
210	215	220
Arg Arg Gln Ala Lys Lys Ile Glu Asn Thr Gly Ser Lys Thr Glu Ser		
225	230	235
Ser Ser Glu Ser Tyr Lys Ala Arg Val Ala Arg Arg Glu Arg Lys Ala		
245	250	255
Ala Lys Thr Leu Gly Val Thr Val Val Ala Phe Met Ile Ser Trp Leu		
260	265	270
Pro Tyr Ser Ile Asp Ser Leu Ile Asp Ala Phe Met Gly Phe Ile Thr		
275	280	285
Pro Ala Cys Ile Tyr Glu Ile Cys Cys Trp Cys Ala Tyr Tyr Asn Ser		
290	295	300
Ala Met Asn Pro Leu Ile Tyr Ala Leu Phe Tyr Pro Trp Phe Arg Lys		
305	310	315
Ala Ile Lys Val Ile Val Thr Gly Gln Val Leu Lys Asn Ser Ser Ala		
325	330	335
Thr Met Asn Leu Phe Ser Glu His Ile		
340	345	

&lt;210&gt; 3

&lt;211&gt; 9947

&lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 3

```

cttcaggaag acaataatat aataataaca atatttttctt cactctgcag tgtctttaca 60
ttccagggtt gggaacatla ctgaggattc tcttccatt ttccagtttc ctgttcatta 120
ttcttatttt tttagactgt ttttagcatcg ggagcacaaa ggccagtcac caggaattgc 180
aaacaaatgc gtagtcagag agagaggqct cactgcccac ttgtcatgtg gatgcagaca 240
cattgcagat gtgttcccag taacaatgtc ttgagaagag gactggcttt tccaccagca 300
tctcagaat gccgggtgtgt ctaaacagca tgtcgttctt taatgctttc atgcaatata 360
ttttatcaat ctcaagttcc cctcactatg tattataata atttctgctt gttggtaacc 420
aatgcagatg gaaaattgat tcttaacaga agagaaagag ccaagtattg atgcttacta 480
tttacacuct attgtatctt tgaacaaaa acccggtgtg ctaagtattg attgggaaca 540
agggatgggt tcaagtcclat gcactaagga aaaacaaatc ttgggcctaa aacaataatg 600
ataatagaat ttaatataga gtagagacct gttttgtaga ataactttcc tagtaatcac 660
tggtgaaat aatcatactia gttacacacg cgcactacag ggatttcacat gagggatttt 720
cccattgaag gcatttatit auctaaaagg acttcactct taaggcggtn atgcaggaca 780
gataacagau ataaagulaa caagag itga tctttcagct ccataattac atttcattat 840

```

```

aycgacnqgtt gcacagagaa artcaaaaag faaaaataaa atatgaaagg atatttataa 900
kraaaaagaaa ttttatcaaa tlaagaqnaf gaaacattta ttagttagaa caatctccaa 960
taabrttltg caatataatt tttgtcaaat tttatftttgt cataaacatt tgggatttat 1020
aafanaaahg gaaacttgaa aattfafaft ajagataata lclgatcatt tectctggca 1080
lcttggtaga tatgtgtttt ttccgtrayy agtactgaaa ulcaggaaac atctctgtat 1140
ttttgtgata atcaacaagg araaaaatlt tcmatalgta aataaaraqy ttatgagcag 1200
caatfnatuc ctgtctgttg ctgtgcagct ghgctacgcy aagtgaaatg ggtcctgtgt 1260
yaaaatcccc ttctcgccgg galcccyggg gattctgtac atagtgtttg gctttggggc 1320
tgtgtgtggc gtgtttggaa acctcctggf gatgatttca atcctccatt tcaagcagct 1380
gcactctccg accaattttc tegtgtccct tctggcctgc gctgatttct tgggtgggtgt 1440
gactgtgatg cccctcagca tggtcaggac ggtggagagc tgtctgtatt ttgggaggag 1500
tttttgtact ttccacacct gctgtgatgt ggcattttgt tactctctc tctttcactt 1560
gtgcttcac ttccatcgaca ggtacattgc ggttactgac cccctgggtct atctaccac 1620
gttcaccgta tctgtgtcag gaatttgcat cagcgtgtcc tggatcctgc cctcatgta 1680
cagcgggtgt gtgtttctaca caggtgtcta tgacgatggg ctggaggaaat tatctgatgc 1740
cctaactcct ataggaggtt gtcagaccgt tgtaaatcaa aactgggtgt tgacagattt 1800
tctatccttc tttatcccta cctttattat gataattctg tatggtaaca tatttcttgt 1860
ggctagacga caggcgaaaa agatagaaaa tactggtagc aagacagaat catcctcaga 1920
gagttacaaa gccagagtgg ccaggagaga gagaaaagca gctaaaaccc tgggggtcac 1980
agtggtagca tttatgatit catgggtacc atatatgatt gattcattaa ttgatgcctt 2040
tatgggcttt ataacccttg cctgtattta tgagatttgc tgttgggtgt cttattataa 2100
ctcagccaag aatcctttga tttatgcttt attttaccct tgggttagga aagcaataaa 2160
agttattgta actggtcagg ttttaaagaa cagttcagca accatgaatt tgttttctga 2220
acatatataa gcagttgtat agacgaagtt caggatacct ttaaaattac caagcgaaat 2280
gagtttttaa aaatcaagta agactatgaa tgaatagcaa ataaattgct cttcaaatga 2340
aaaacaaatc aatgtttttc agtcttgtta agatgtgcac tttcctgtcc cttctgcaaa 2400
agtatttact tggctaacaa atgtttaaatt cctatttgtt aactgcttta gagctcagca 2460
tatccacctc cctgcagaca ctttttgtct ttttaaccat tgactcttcc ctctgctctg 2520
gtatttttcc taaaaatatt tgtttttttt tttttattta ttccctttcc tcttttcttt 2580
acaaagcttt ctactcttcc ccagcctgcc aaaaatttca tttgtgaata gcctttatca 2640
aattattggg ttcttttgtc ttgggtattt taccacagga gtcccttttag gtatttaattt 2700
aattatttca atcttggggg agatctcagg gtgtatgggg caatttgcaa atgaagacat 2760
catcttgacc aggcgttgtt aattgtcaaa ccagtactg tcattcttgt aattatttcc 2820
tcccccaaag tgggaagcag aagccactgt acttcccaga atgatgttag gatgattatt 2880
tggctgtgtt tcttgcattt gcacaaaact gtttaaagag ttgggtatgaa tagagccctg 2940
tgttacatta ttcagttcat ttttctcttt ttttttctat attaaaactt aattacagca 3060
tcaagtgcag tctctagctt gccatgtgga atatacatca atgagaagca ttcagggtatt 3120
aggaatttgc aagattagaa accaaacatg aaacctgtgc ctatattgta tggaaatcag 3180
tgctagatgc cttagacaca ggcataacat cccatttttg tctttaataa gctgtgactc 3240
tggcaagaag caatgttgtt cactgaaaat tttaaaaagg gcgaacacta gctcaaccag 3300
gtaattaaag ttcaatatca gtagtagtaa ggcattgtggc tatttgttgt tcttgacatt 3360
atgtaatgag aatggctttt acctctatgt ccttcttccc caaatccat aaccccatg 3420
tagtcatgag aaaaatgtca gatcggaact tatcggaat attctgcata atatttgatc 3480
agtatttctc aaaactgtca gtcatcaaaa ataaagtatg agaaactgtc atgatctaca 3540
ggaaactaag aagacatgac aactaaacgt agtatggcat cctaaatgga aagctagaaa 3600
gaaaagggac attaggggaa gtgaggaaat ccgaataatg aatggaaatt ttattgctat 3660
attgataaca atattggatc attagtatat acaaatgtac tatatgagtt taagatgtta 3720
atgagaaact tcttgcaagg ttctcattac tatctttgca atttttcagt 3780
aattctacaa ctattctgaa attaaaagtt tattcaaaaa atatagagta cacaattcct 3840
gcttgataaa gtttctagcc tgtctatgtg aagacagcaa agcacttatc cttacagtca 3900
ttcatttatt cattctgaat atatctttga agactgagtg tgtactagac tcttgggttca 3960
gtgtgatcag gaatagaaaa ccaggaactt agaattttt gtggcaaac ccaaatacc 4020
agtaattaaq acttggatg catgggaatt taagctataa aaggctgtgt ttaaggaaca 4080
caggagaaq gagaattcag acctggatgg aaaaatgaag agatgtatta aagaagtggc 4140
attcaagtag ggccttaaat tttagaagg atttttgtat gagggaagg atgggaagcg 4200
attttcaggc atgagcaaa gtggttcacy cctgttaalc ggtttaggaa tatgaaaaa 4260
aaacaactay gctgggcgtg caaagatcag aaagatcag aacagcttg cttaacaggt gaaacccct 4320
cggggtggat cacaagggtc ttatctggat gtggtggca utuutytag tcccaactt 4380
ctctactaaa aatacaaaaa ftabctggat gtggtggca tttttttg atgtagccca 4440
tcgggagggt gaggcaggag aatctcttga acctgggag tttttttg atgtagccca 4500

```

atcatgcc	ctgtactcca	gcctgggtga	cagagtgaaa	ctclatcaaa	aaaaaaaga	4560
aaaaaaaga	aaaaaagaaa	gaaagaaaal	aaaacaaata	aaaaccacc	aagaagcaag	4620
agtagtcc	gcttttaaac	cctcccaagg	ttggaalcca	aaacgtgcac	ctctacttct	4680
cctgggcatc	ctccattgtg	gtttggagac	attctccct	ctctgctcaa	gttctactct	4740
ccataattgl	lttclaaagaa	acattttctca	attgaaggti	taaaagacag	tcacttata	4800
aaatgctcca	aggaaaaaqa	tttctgattc	aaadaalgtll	tggaactglt	gtaactctt	4860
ttctgttttt	ggagaacact	gtatatgtgg	atattaaaga	ctclgagaag	tcctgtttta	4920
ucaaaaacct	gtccaatttt	gtttaaatgt	gcatttctaaa	cattttattaa	accatgggta	4980
ctcttttgat	atgaggagct	caataacaga	gctattgtcc	aaggaaaaata	tttaagggaac	5040
accatctcta	tcgttgattt	ggttcttacc	taatglatta	ttaatcttgt	attgggtcttt	5100
tggctcttca	catacaatac	acttcattca	atttgatttt	ctaaaaggta	gagggtgggtt	5160
tccaacctat	ggtataataa	tgagtaagca	ctcataacat	gttttttttt	gtcaattatg	5220
atgtataaga	ttaattgtac	agtatgtaaa	atgggataaa	ttatgtgact	ttgaaggagg	5280
gactggatgc	tcgagactga	aaaatctcag	aagggtccat	ggagaactta	gaatataata	5340
ccagctaagc	agtggaggat	tggtttaaat	agaaaaaaca	atagtagaaa	aggaatttct	5400
aggcagaata	aaaatctcat	gaaaggata	aatttagtgg	tgcatcaaat	gcaattaaag	5460
atacaaaaaa	ggatagccaa	taagatcagt	cggcctaaa	cacaccattt	gggtaagaga	5520
gtcacaaatca	atctatccat	caatcaacat	actattttta	gccctataat	tgactgttcc	5580
agtatggtag	ccatgagcaa	catgtggtta	ttgaggactt	gaaatgtggc	tagtctgagc	5640
tgagatattc	tataggtaga	atttatatac	cagatttcaa	agacaaacaa	aagaatgtaa	5700
gatgtctctt	tttaaaatat	tgattacatg	ttgaaattat	caattttggg	atgtattggg	5760
ttaaataaaa	atatgttatt	tagatttaatt	tctcttttct	ctttttactt	tttaaaatgt	5820
ggctactaga	aaaatgtaaa	attatgtatg	tagcttaaat	tatatattcta	ttggacagca	5880
ctactctaga	gaaaacaaaa	atgagccata	ggacaattct	agccctccag	gacttaaaaa	5940
tcaagatggg	gagagaatgc	atgaacataa	acaatgaagt	aaatatatat	gaactatggg	6000
aaaagttaaa	ttaattttat	ttagcaattg	atgtttaaaa	acagaggtag	aaaactcata	6060
ttaatcttat	agtctgggtca	ttttataaat	gagaaaaattg	ggactcagag	agaaataaat	6120
taacttgcatt	gaaattatatac	agctagttag	ctagggtcgg	ttgctcacgc	ctgtaattctc	6180
agcactttgg	gaagctgaag	tgggaggatc	acttgagttc	aggagtttga	taccagcctg	6240
ggcaacatag	tgagaccttg	tctgtactaa	aaatgaaaaa	gttagccagg	cggtggtggg	6300
aatgcctgta	gtcccagcta	ctcaggaggc	tcagggtggga	ggatcacttg	tacacaggag	6360
tttgaggctg	cagtggagcag	tgatcgcatc	tagaaaacaaa	gtgagattct	gtctcaaaaa	6420
ataaaaagtt	atacagtttag	caaaaaatct	ttgccatact	ttgaacccaa	attatttgaa	6480
ttctaagctc	aaattttttt	ctcgacatgg	aaatgagagt	ttaggacaaa	caataaggga	6540
tattacaaag	aagtacagtt	aaataaatgc	tatccacaag	aagatattta	gcatttagag	6600
tttctctcat	aagtcagtg	ttcttgataa	tttttagatc	atagtcacat	tgaaatatgc	6660
tgaaatctat	gtattctttc	tctagaaaaa	tgacacacat	cacatatata	caatatttag	6720
tgtactattc	tgggggttcc	ataacctttg	gggccaatta	cagggtcatgg	atacactgtt	6780
cctaagctgg	gcatagacta	gacttgctg	aagtgaatac	gacctcaact	aactctgttg	6840
cttaacacaa	caaagggtta	tttctgtctc	atgtgaagtc	cactatgagt	ctgaggagat	6900
atcagggcaa	ttgtctctaa	catagtgcag	gttgccttga	tttcatggct	ccatcttttc	6960
aacaagagac	ttctataact	cagcctgaaa	gaacacatga	acacttaaat	ctatttagcca	7020
gaaccaagca	gacagtccac	ctaattggctt	gaaaaacaca	ggacgataag	cacaatgttt	7080
gctgcacaca	aaggcctctt	ctttacttga	tggaacatca	tggaacatca	cattgtgtga	7140
atgagtatac	tctcagggtt	tcaatttggc	agaaaaatgt	ttaaactcat	tagtgtttat	7200
tttaatcaat	attaagtcta	agtgagatag	ttgctggctt	cggctggctg	actcaagtat	7260
gttagagtca	aggatgctgt	acagattttc	ctgatgcttg	tctaattggt	ccaaagtga	7320
tacaggagtt	ccagccaaat	cacacatgtt	cctggaaata	gggaggagga	agacctagga	7380
agaggggctc	tctgaagccc	tacttgacaa	cttcagtttc	cccaagggag	agaagattct	7440
gatgctatgg	aggaaattaa	cccattgggt	gttaggtgag	aaataagcat	ttctgccaca	7500
tgaagtaatc	tggaaaaatga	aatccaacaa	gtgaaaaata	aacttcttac	caaatctctt	7560
cacagggtatt	tgctgtataa	atccataagg	aagtgaactg	agaaaaagag	aatggaaaaa	7620
ataacaggtt	ttctcaaaaga	tctctatacc	atctttttct	taaacttctc	cttttgtaatt	7680
atttagtatt	aattttttcag	ccaatgaaca	tgtactatat	atgtgttaca	tagtaaatgc	7740
cctgttgaca	atgcagaagt	gatgagaatg	aatgagactc	aatcgtttta	gtagagtttt	7800
caalatttcc	caaaaggtag	tggttacaag	cagayccaga	cagccagtcc	ttttatggga	7860
caaagatatac	ttgtctagaga	tcacacagtg	ggtcagcatc	agggacagag	tccccagaat	7920
ttgcaatagc	ctgggtgtta	ttgtcttggg	gaaatcagta	gaaacatgta	aaggcatatt	7980
ttttaatttt	acatttcaag	gtacatgtgc	agyatgtgca	ggtttgttac	ataggtaaac	8040
atgtgcatat	gtggtttgtt	gcacctatca	atccatcaac	taggtaktta	gcccagcatg	8100
cattaagctat	tttccataat	gtctctgtgc	atccatcaac	cctcttctca	caggccatca	8160

```

tggtgtatgc tcccttccct gtgtcttltgt attctcattg ttcagctctt actgaagaat 8220
caatattatg aaaatggcna tal tggcccaa agcaatttat agattttaatg ctatttccai 8280
tactactanca ttgacattct tcaacagaatt agaaaaaaa gattttcaaaa ttctatfaga 8340
atttaaaaaa agctcgtala qccagucnaa luctaagcaa aaagaacnaa acaaaaagag 8400
caccacagga cccaacttca aactatacta caaggctara ytaacnaaa cagcatyglia 8460
ctgttlaaaa accggcacat agaccaatgg aacagaatag agaaclnaaa aalgaanaaa 8520
taaaclaga atcatctggt cttaacaaa cttgacaaaa aaacaagala ttggqaaagi 8580
atttccattt taataaatgg tgclggaaga actggctagc catatgcaaa aaaattgaaa 8640
ctggggccct tccttacatc ctatacaaga attaactcaa gacagattaa agacttaaat 8700
gcaagaacaa ttaatatctt actagtaggg ctgccctcta ccagatggct aatggagtca 8760
cgatgcagag ctatgagatg gagggcaggg gatgctatgg ctaattttta ccacagcagc 8820
aaacacagaa aaaccacta ggtcgatatag actcctgacc agccccagca tcagatcttg 8880
gtcactgtgg gctatggtga attcataatt caaaacccaa agcctaattt ctgttgtgtt 8940
tggaataaaa ttctaactct gtgattctga tctatgaggc ttgcatagt cttagccccg 9000
cacaactctc taccactac ctattctgct ctccctttac ttgttatgct ccaaataat 9060
ttgtccaatc ccagccctc ggctacccc caccaggatgc ctccaggagct gtgactggc 9120
tatcccatct gttgtactag gtgcctcagg agactcgac agggtttttc atctgttga 9180
tcaactcagc ctcatgctt caaggagctg gttccttaca caggctctcag ctttaacatc 9240
gtccctcag aaaaatcaag atctcggtca atgttgttat ccatgtttta ttcttttact 9300
caccttgttt ttatatcatt tccttcatgg tacatatcag aatgtgttac aatcttattc 9360
atctgtttat ttcttgtgt tttaactgtc tgtctcttaa tgacatgtaa gctgcaggag 9420
gtcagatact tgcgaagta tcactatgag taaatcagac agtttgtact ggtgtttat 9480
ttctttgtc ctatgttgtt gttttacttt ggtcagttga gtaataaat gagtgaataa 9540
ataaaataga aatagattcc ccagcattgg gaggatacat taaatgtatt cttttttttt 9600
tttttaagt tctgggttac atgtgctgga tgtgcagttt tcttacatag gtaaatgtgt 9660
gccatggtgg ttgtgtgcac ctatcaactc attacctagt tattaagcct ggaaaaatgc 9720
attcttttta taagcttttt tggggagggg cagggtcttg ctgtgaccta ggctggggt 9780
cagtggcatg atcatagctc aatgcagctc caaactcctg ggctcagggt acactcccat 9840
gtagctgggg ctacaggcgt gtgcgaccat gcctggctaa ttttttaaaa aaattttatt 9900
ttgtagaaaa gggatctcat ttgttgccc aggttggtct caaacac 9947

```

&lt;210&gt; 4

&lt;211&gt; 101

&lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 4

```

gaacagttca gcaaccatga atttgttttc tgaacatata taagcagttg katagacgaa 60
gttcaggata cctttaaaaat taccaagcga aatgagtttt t 101

```

&lt;210&gt; 5

&lt;211&gt; 321

&lt;212&gt; PRT

&lt;213&gt; Human

&lt;400&gt; 5

```

Cys Tyr Gln Val Asn Gly Ser Cys Pro Arg Thr Val His Thr Leu Gly
1          5          10          15
Ile Gln Leu Val Ile Tyr Leu Thr Cys Ala Ala Gly Met Leu Ile Ile
20          25          30
Val Leu Gly Asn Val Phe Val Ala Phe Ala Val Ser Tyr Phe Lys Ala
35          40          45
Leu His Thr Pro Thr Asn Phe Leu Leu Leu Ser Leu Ala Leu Ala Asp
50          55          60
Met Phe Leu Gly Leu Val Leu Pro Leu Ser Thr Ile Arg Ser Val
65          70          75          80
Glu Ser Cys Trp Phe Phe Gly Asp Phe Leu Cys Arg Leu His Thr Tyr
85          90          95
Leu Asp Thr Leu Phe Cys Leu Thr Ser Ile Phe His Leu Cys Phe Ile

```

```

      100      105      110
Ser Ile Asp Arg His Cys Ala Ile Cys Asp Pro Leu Leu Tyr Pro Ser
      115      120      125
Lys Phe Thr Val Arg Val Ala Leu Arg Tyr Ile Leu Ala Gly Trp Gly
      130      135      140
Val Pro Ala Ala Tyr Thr Ser Leu Phe Leu Tyr Thr Asp Val Val Glu
      145      150      155      160
Thr Arg Leu Ser Gln Trp Leu Glu Glu Met Pro Cys Val Gly Ser Cys
      165      170      175
Gln Leu Leu Leu Asn Lys Phe Trp Gly Trp Leu Asn Phe Pro Leu Phe
      180      185      190
Phe Val Pro Cys Leu Ile Met Ile Ser Leu Tyr Val Lys Ile Phe Val
      195      200      205
Val Ala Thr Arg Gln Ala Gln Gln Ile Thr Thr Leu Ser Lys Ser Leu
      210      215      220
Ala Gly Ala Ala Lys His Glu Arg Lys Ala Ala Lys Thr Leu Gly Ile
      225      230      235      240
Val Val Gly Ile Tyr Leu Leu Cys Trp Leu Pro Phe Thr Ile Asp Thr
      245      250      255
Met Val Asp Ser Leu Leu His Phe Ile Thr Pro Pro Leu Val Phe Asp
      260      265      270
Ile Phe Ile Trp Phe Ala Tyr Phe Asn Ser Ala Cys Asn Pro Ile Ile
      275      280      285
Tyr Val Phe Ser Tyr Gln Trp Phe Arg Lys Ala Leu Lys Leu Thr Leu
      290      295      300
Ser Gln Lys Val Phe Ser Pro Gln Thr Arg Thr Val Asp Leu Tyr Gln
      305      310      315      320
Glu

```

<210> 6  
 <211> 296  
 <212> PRT  
 <213> Human

```

<400> 6
Leu Phe Gly Asn Leu Val Ile Met Val Ser Ile Ser His Phe Lys Gln
  1      5      10      15
Leu His Ser Pro Thr Asn Phe Leu Ile Leu Ser Met Ala Thr Thr Asp
      20      25      30
Phe Leu Leu Gly Phe Val Ile Met Pro Tyr Ser Ile Met Arg Ser Val
      35      40      45
Glu Ser Cys Trp Tyr Phe Gly Asp Gly Phe Cys Lys Phe His Thr Ser
      50      55      60
Phe Asp Met Met Leu Arg Leu Thr Ser Ile Phe His Leu Cys Ser Ile
      65      70      75      80
Ala Ile Asp Arg Phe Tyr Ala Val Cys Tyr Pro Leu His Tyr Thr Thr
      85      90      95
Lys Met Thr Asn Ser Thr Ile Lys Gln Leu Leu Ala Phe Cys Trp Ser
      100      105      110
Val Pro Ala Leu Phe Ser Phe Gly Leu Val Leu Ser Glu Ala Asp Val
      115      120      125
Ser Gly Met Gln Ser Tyr Lys Ile Leu Val Ala Cys Phe Asn Phe Cys
      130      135      140
Ala Leu Thr Phe Asn Lys Phe Trp Gly Thr Ile Leu Phe Thr Thr Cys
      145      150      155      160
Phe Phe Thr Pro Gly Ser Ile Met Val Gly Ile Tyr Gly Lys Ile Phe
      165      170      175
Ile Val Ser Lys Gln His Ala Arg Val Ile Ser His Val Pro Glu Asn
      180      185      190

```

Thr	Lys	Gly	Ala	Val	Lys	Lys	His	Leu	Ser	Lys	Lys	Lys	Asp	Arg	Lys
	195						200						205		
Ala	Ala	Lys	Thr	Leu	Gly	Ile	Val	Met	Gly	Val	Phe	Leu	Ala	Cys	Trp
	210					215						220			
Leu	Pro	Cys	Phe	Leu	Ala	Val	Leu	Ile	Asp	Pro	Tyr	Leu	Asp	Tyr	Ser
	225				230					235					240
Thr	Pro	Ile	Leu	Ile	Leu	Asp	Leu	Leu	Val	Trp	Leu	Arg	Tyr	Phe	Asn
			245						250						255
Ser	Thr	Cys	Asn	Pro	Leu	Ile	His	Gly	Phe	Phe	Asn	Pro	Trp	Phe	Gln
			260					265						270	
Lys	Ala	Phe	Lys	Tyr	Ile	Val	Ser	Gly	Lys	Ile	Phe	Ser	Ser	His	Ser
		275					280						285		
Glu	Thr	Ala	Asn	Leu	Phe	Pro	Glu								
	290					295									

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
2 May 2002 (02.05.2002)

PCT

(10) International Publication Number  
WO 02/034913 A3

(51) International Patent Classification<sup>7</sup>: C12N 15/12,  
C07K 14/705, 16/28, A01K 67/027, G01N 33/53, C12Q  
1/68, G01N 33/68, 33/50, A61K 38/17

(74) Agent: MILLMAN, Robert, A.; Celera Genomics, 45  
West Gude Drive C2-4#20, Rockville, MD 20850 (US).

(21) International Application Number: PCT/US01/31454

(22) International Filing Date: 9 October 2001 (09.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/694,821 24 October 2000 (24.10.2000) US  
09/781,559 13 February 2001 (13.02.2001) US

(71) Applicant: PE CORPORATION (NY) [US/US]; 761  
Main Avenue, Norwalk, CT 06859 (US).

(72) Inventors: WEI, Ming-Hui; Celera Genomics Corpora-  
tion, 45 West Gude Drive C2-4#20, Rockville, MD 20850  
(US). YAN, Chunhua; Celera Genomics, 45 West Gude  
Drive, Rockville, MD 20850 (US). KETCHUM, Karen,  
A.; Celera Genomics, 45 West Gude Drive C2-4#20,  
Rockville, MD 20850 (US). CRAVCHIK, Anibal; Celera  
Genomics, 45 West Gude Drive, Rockville, MD 20850  
(US). DI FRANCESCO, Valentina; Celera Genomics, 45  
West Gude Drive, Rockville, MD 20850 (US). BEASLEY,  
Ellen, M.; Celera Genomics, 45 West Gude Drive,  
Rockville, MD 20850 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,  
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA,  
ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
TG).

**Published:**

— with international search report

(88) Date of publication of the international search report:  
31 October 2002

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: ISOLATED HUMAN G-PROTEIN COUPLED RECEPTORS, NUCLEIC ACID MOLECULES ENCODING HUMAN  
GPCR PROTEINS, AND USES THEREOF

(57) Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the Human  
genome, the GPCR peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid  
molecules, methods of identifying orthologs and paralogs of the GPCR peptides and methods of identifying modulators of the GPCR  
peptides.



WO 02/034913 A3

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 01/31454

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/705 C07K16/28 A01K67/027 G01N33/53  
C12Q1/68 G01N33/68 G01N33/50 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A01K G01N C12Q A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

SEQUENCE SEARCH

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 00 60081 A (SYNAPTIC PHARM CORP (US) BOROWSKI PATHIRANA OGOZALEK LICHTBLAU BONINI) 12 October 2000 (2000-10-12) SEQ ID NO:21, 22 page 5 page 10; figures 21,22 page 14 page 18 -page 19 page 21 -page 23; figure 25; tables 1-8 page 48; claim 17 page 53; claims 39,40</p> <p style="text-align: center;">--- -/-</p>	1-23



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

11 July 2002

Date of mailing of the international search report

31/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Macchia, G

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 01/31454

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 01 36473 A (PHARMACIA & UPJOHN CO (US) VOGELI WOOD PARODI HIEBSCH LIND SLIGHTOM ET) 25 May 2001 (2001-05-25) nGPCR40, SEQ ID NO:83, 84 page 14; table 1 page 90 -page 91 page 103 -page 104 page 119 -page 120 page 152 -page 166; claims -----	1-23
P,X	BOROWSKY B. ET AL.: "Trace amines: Identification of a family of mammalian G protein-coupled receptors" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 98, no. 16, 31 July 2001 (2001-07-31), pages 8966-8971, XP002185201 ISSN: 0027-8424 the whole document	1,2,4,5, 8,9, 20-23
P,X	-& DATABASE EMBL 'Online! 2 August 2001 (2001-08-02) "Homo sapiens trace amine receptor 4 (TA4) gene, complete cds." Database accession no. AF380192 XP002205531 the whole document -----	1,2,4,5, 8,9, 20-23

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 01/31454

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claim 18 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 12, 17, 18 all in part  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

Continuation of Box I.2

Claims Nos.: 12, 17, 18 all in part

Present claim 12 relates to a method involving an agent defined by reference to a desirable characteristic or property, namely its capability to allow detection of the peptides of claim 2.

Present claim 17 relates to a composition comprising an agent defined by reference to a desirable characteristic or property, namely its capability to bind to the peptides of claim 2.

Present claim 18 relates to a therapeutical application of said agent.

The claims cover all agents having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such agents, namely antibodies against the polypeptide(s) disclosed in present application.

In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define an agent by reference to a result to be achieved.

Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to antibodies against the polypeptide(s) disclosed in present application and, where applicable, to polypeptides derived from the one disclosed in present application.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/31454

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0060081	A	12-10-2000	US 6117990 A	12-09-2000
			AU 4209500 A	23-10-2000
			EP 1084238 A1	21-03-2001
			WO 0060081 A1	12-10-2000
WO 0136473	A	25-05-2001	AU 1617801 A	30-05-2001
			WO 0136473 A2	25-05-2001